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Abstract

Mycoplasma hyopneumoniae is the causal agent of mycoplasmal pneumonia; a mild
chronic respiratory disease of pigs that is characterised by a dry, non-productive cough
and the sequential development of microscopic and macroscopic lesions of the
respiratory tract and lung. Strains of M. hyopneumoniae vary in pathogenicity; however,
a major driver of lung pathology is the host immune response to infection. Although the
underlying inflammatory mechanisms are ill-defined, secretion of pro-inflammatory
cytokines is purported to play a role in host-mediated lung tissue damage. Enhanced
activation of M. hyopneumoniae surface-bound plasminogen to plasmin, a potent
stimulus and chemoattractant of pro-inflammatory cells, also raises the question of
whether pathogen-exploitation of the host plasminogen activation system contributes to
pathogenicity. Commercial inactivated whole-cell preparations (bacterins) can reduce
clinical signs of disease and regulate the secretion of pro-inflammatory cytokines, but
they do not prevent the colonisation of swine by M. hyopneumoniae, thus necessitating
alternative vaccination strategies. A prerequisite for M. hyopneumoniae pathogenesis is
adherence to ciliated respiratory epithelia; a multifactorial process involving an array of
adhesins including those belonging to the P97/P102 paralog family. Of the P97/P102
paralog family of proteins, only P97 has been investigated as a potential vaccine
candidate. Whilst partial protection against lung pathology was observed in vaccinated
pigs, it was hypothesised that administration of multiple antigens from the P97/P102
paralog family may result in a superior level of protection against M. hyopneumoniae
infection.
In this study, two Australian M. hyopneumoniae field strains (Hillcrest and Beaufort)
were compared for their ability to induce mycoplasmal pneumonia. The optimum strain
for use in a subsequent vaccine trial was determined by combining clinical observations
with pathologic and histopathologic examination of tissue samples from challenged
pigs. Pig serological and mucosal responses to recombinant subunit vaccines containing
functional domains of eight of the P97/P102 paralogs formulated with Alhydrogel® or
Montanide™ Gel01 were then compared with a commercial bacterin (Suvaxyn® M.
hyo) following experimental challenge with the more virulent of the two field isolates.
Cytokine levels (interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α) in
Page | xv

tracheobronchial lavage fluid (TBLF) were assessed and a M. hyopneumoniae-specific
quantitative PCR assay confirmed the presence of mycoplasmal DNA in the TBLF of
challenged pigs. Damage to the ciliated respiratory epithelium of challenged pigs was
evaluated by scanning electron microscopy of fixed tracheal samples collected six
weeks post-infection (wpi) with the Hillcrest strain. Finally, TBLF collected from
Suvaxyn®-vaccinated and unvaccinated pigs were examined for plasmin activity and
these results were correlated with individual cytokine responses and bacterial load data.
The results of the challenge study indicated that a single dose of the Hillcrest strain
induced significantly higher coughing scores and gross and histological lesions
symptomatic of mycoplasmal pneumonia during the first 3-4 weeks after challenge,
relative to the less virulent Beaufort strain. As such, M. hyopneumoniae Hillcrest was
employed as a challenge strain in the subsequent vaccine trial. While mycoplasmal
pneumonia was successfully induced during the vaccine trial using the Hillcrest strain,
the vaccine formulations varied in their efficacy in protecting against disease. Despite
inducing significant systemic immune responses, the Alhydrogel® and Montanide™
Gel01 formulations failed to stimulate significant post-vaccination mucosal immunity,
and were unable to regulate the secretion of IL-1β, IL-6 and TNF-α in the porcine
airways in response to M. hyopneumoniae challenge. In contrast, Suvaxyn® M. hyo
administration induced significant mucosal immunity and regulated the secretion of proinflammatory cytokines, resulting in superior reduction of clinical signs of disease and
bacterial load in the porcine airways relative to immunisation with the recombinant
formulations. The Alhydrogel® and Montanide™ Gel01 formulations did, however,
offer comparable protection against damage to epithelial cilia. Plasmin activity in the
porcine airways was significantly enhanced in unvaccinated pigs, but not Suvaxyn® M.
hyo vaccinates, during experimental infection, and was positively correlated with IL-1β,
IL-6 and TNF-α responses and bacterial load in the TBLF of challenged animals. In
conclusion this study highlights the impact of M. hyopneumoniae strain virulence on the
course of clinical disease, and the importance of selecting an appropriate strain for use
in experimental challenge systems to evaluate vaccine efficacy. The results also
emphasize the importance of pro-inflammatory cytokine responses and plasmin activity
as mediators of lung tissue damage, and illustrate that plasminogen activation in the
porcine respiratory tract is ameliorated by administration of the partially protective
bacterin Suvaxyn® M. hyo. Finally, this study highlights the need for further research
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into the P97/P102 paralogs as protective antigens and optimisation of vaccine strategies
that will induce protective immunity against M. hyopneumoniae infection.
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Chapter 1: Review of Literature

1.1 Mycoplasmas
Mycoplasmas are the largest genus of the class Mollicutes (mollis, soft; cutis, skin)
(Razin, 1995a) and can be phenotypically distinguished from other bacteria by their
minuscule size (lengths as small as 0.3 µm) (Cossart and Lecuit, 2000) and the absence
of a cell wall (Razin et al. 1998). Bound only by a cell membrane, the bacteria are
predominantly spherical; however, they can exhibit a variety of morphologies, including
flask and pear shapes (Razin et al. 1998).
Members of the Mycoplasma genus are believed to have evolved by genome
reduction from low guanine (G) and cytosine (C) content gram-positive bacteria that are
phylogenetically related to bacilli, clostridia, enterococci, lactobacilli, staphylococci and
streptococci (Rogers et al. 1985; Woese et al. 1980). As a consequence of this,
mycoplasma genomes are the smallest of any self-replicating microorganism, ranging in
size from 580 kb (Mycoplasma genitalium; Fraser et al. 1995) to 1350 kb (Mycoplasma
penetrans; Sasaki et al. 2002). Furthermore, their genomes are rich in adenine (A) and
thymine (T); G+C content typically ranges from 24-33 mol% (Razin et al. 1998), which
is low given the minimum G+C composition requirement for bacteria to encode
essential structural genes is approximately 25 mol% (Maniloff, 1996). In addition, G+C
distribution along mycoplasma genomes is uneven, with coding regions being
frequently rich in G+C content and non-coding regions having high (up to 90 mol%)
A+T content (Dybvig and Voelker, 1996; Razin et al. 1998; Sirand-Pugnet et al. 2007).
The bias towards A-T base composition in mycoplasma genomes has led to codon usage
which differs from the universal genetic code; the UGA codon encodes for tryptophan
in mycoplasmas rather than a stop codon as in other organisms (Samuelsson and Boren,
1992). This complicates expression of mycoplasma gene products in other bacterial
species, such as Escherichia coli, and necessitates prior mutation of all in-frame UGA
codons to UGG so as to encode tryptophan in the transformed bacteria (Baseman and
Tully, 1997; Hsu et al. 1997). The genomic sequences of Mycoplasma species are also
unique in that they often include heterogeneous transcription initiation sites, leaderless
mRNAs and lack a strong -35 consensus sequence if such a region is at all present
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(Taschke et al. 1987; Taschke et al. 1988; Markham et al. 1994; Weiner et al. 2000;
Musatovova et al. 2003). Additionally, the Shine-Dalgarno sequence, when present,
varies between Mycoplasma species (Christiansen et al. 1994; Shibata et al. 1995;
Cheng et al. 1996; Weiner et al. 2000). Collectively, these features have meant that
transcription and translation initiation signals in mycoplasmas are ill-defined.
The primary reason for mycoplasmas having evolved regressively to possess only
those genes which are necessary to maintain basic core functions (Vasconcelos et al.
2005) is thought to be the process of adaptation to a parasitic lifestyle (Koonin, 2000),
one that is both host and tissue specific (Clark, 2005; Pitcher and Nicholas, 2005). Host
organisms include mammals, reptiles and fish (Razin, 1992), of which mycoplasmas
predominantly inhabit the mucosal surfaces of the respiratory and urogenital tracts
(Razin, 1995b; Athamna et al. 1997; Boguslavsky et al. 2000). Despite their fastidious
nature, mycoplasmas are efficient at colonising their hosts and are the causative agents
of a variety of diseases that may take a chronic course (Baseman and Tully, 1997)
and/or increase host susceptibility to secondary pathogens (Asai et al. 1996) (Table 1.1).
The focus of this thesis is on the swine pathogen Mycoplasma hyopneumoniae, with the
following sections dedicated to summarising the characteristics of M. hyopneumoniae
related to pathogenesis, control measures and experimental subunit vaccines.
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Table 1.1 An overview of animal diseases associated with infection by selected pathogenic
members of the Mycoplasma genus.
Mycoplasma

Host

Disease

Reference

Ruminants

Mastitis, arthritis,

DaMassa et al. (1992)

species
M. agalactiae

keratoconjunctivitis, abortion
M. alligatoris

Alligators

Necrotic epicarditis, pericarditis,

Brown et al. (2001)

myocarditis
M. arthritidis

Rodents

Polyarthritis

Cole et al. (1971)

M. bovis

Bovines

Pneumonia, mastitis and arthritis

Nagatomo et al. (2001)

M. bovoculi

Bovines

Keratoconjunctivitis

Levisohn et al. (2004)

M. capricolum

Goats

Contagious caprine

Manso-Silavn et al. (2011)

pleuropneumonia
M. cynos

Canines

Pneumonia

Rosendal, (1972)

M. gallisepticum

Poultry

Chronic respiratory disease

Boguslavsky et al. (2000)

M. haemofelis

Felines

Hemolytic anemia

Tasker, (2010)

M. hyopneumoniae

Swine

Mycoplasmal pneumonia

Ross, (1986)

M. hyorhinis

Swine

Polyserositis, arthritis, otitis

Morita et al. (1999)

M. hyosynoviae

Swine

Arthritis

Ross and Duncan, (1970);
Nielsen et al. (2001)

M. leachii

Bovines

Pneumonia, mastitis, polyarthritis,

Tardy et al. (2009)

abortion
M. mycoides

Goats

Mastitis, arthritis, pleurisy,

DaMassa et al. (1992)

pneumonia, keratoconjunctivitis
M. ovipneumoniae

Sheep &

Nonprogressive pneumonia

Goats
M. pulmonis

Rodents

Goltz et al. (1986);
Besser et al. (2008)

Murine respiratory

Chambaud et al. (2001)

mycoplasmosis
M. putrefaciens

Goats

Mastitis, arthritis,

Thiaucourt and Bolske

keratoconjunctivitis, pneumonia,

(1996)

septicaemia
M. suis

Swine

Acute haemolytic disease

Henry, (1979);
Messick, (2004)
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1.2 Mycoplasma hyopneumoniae
M. hyopneumoniae are small (400 nm to 1200 nm) (Mebus and Underdahl, 1977;
Tajima and Yagihashi, 1982) bacteria belonging to the order Mycoplasmatales (Razin
and Hermann, 2002) and were first isolated from the pneumonic lungs of swine nearly
50 years ago (Goodwin et al. 1965; Mare and Switzer, 1965). They are the causative
agent of mycoplasmal pneumonia; a mild, chronic pneumonia of pigs (Ross, 1986;
Ross, 1992; Sibila et al. 2009) which occurs across the globe with high prevalence (38%
to 100%) in virtually all areas of pig production (Guerrero, 1990; Thacker and Minion,
2010). Transmission of M. hyopneumoniae is primarily via nose-to-nose contact with
carrier swine or by means of aerosols expelled during bouts of coughing from infected
pigs (Williams, 1983; Czaja et al. 2002), and can occur amongst penmates independent
of age (Etheridge et al. 1979; Piffer and Ross, 1984). Aerosol transmission of M.
hyopneumoniae between herds has also been documented for distances up to 9.2 km
(Otake et al. 2010). Once infection is established, M. hyopneumoniae is maintained in
most herds by direct sow-to-pig exposure (Calsamiglia and Pijoan 2000; Rautiainen and
Wallgren, 2001).
M. hyopneumoniae infection is not associated with high mortality rates; however, it
predisposes the host to more severe secondary respiratory pathogens such as Pasteurella
multocida, Actinobacillus pleuropneumoniae and viruses including swine influenza and
porcine reproductive and respiratory syndrome virus (PRRSV) (Sorensen et al. 1997;
Thacker, 2006). Such multifactorial infections exacerbate clinical disease to produce
complicated pneumonias referred to as enzootic pneumonia and the porcine respiratory
disease complex (Sorensen et al. 1997; Thacker, 2006).
The exact economic losses attributed to M. hyopneumoniae-infection are often
difficult to ascertain because of co-infections with other respiratory pathogens and
associated reduced daily weight gain, reduced feed efficiency and increased medication
costs (Thacker and Minion, 2012); however, M. hyopneumoniae infections are
estimated to cost pig producers more than $20 million per annum in Australia and up to
$1 billion per annum in the major swine rearing countries (Clark et al. 1991).
Consequently, the control and eradication of M. hyopneumoniae is paramount to
reducing global economic impact of infection (Ross, 1986) and improving the health of
pigs (Thacker et al. 1999; Thacker, 2004; Wilson et al. 2012).
Page | 4

1.2.1 Mycoplasmal pneumonia
M. hyopneumoniae has long been identified as the pathogen responsible for porcine
mycoplasmal pneumonia; a common and economically important disease within the
swine industry that is characterised by low mortality and high morbidity rates (Ross,
1986). Clinically, mycoplasmal pneumonia is characterised by a dry, non-productive
cough that is most evident when pigs are active (Maes et al. 1996; Sibila et al. 2009).
The onset of coughing in pathogen-free pigs experimentally infected with M.
hyopneumoniae ranges from 7-25 days post-inoculation (pi) (Sorensen et al. 1997;
Irigoyen et al. 1998; Kwon et al. 2002; Lorenzo et al. 2006; Vicca et al. 2003; Villarreal
et al. 2011) and will depend on the virulence of the isolate (Villarreal et al. 2011). In the
field, coughing varies greatly and may be infrequent or absent in some infected animals
(Ross, 1986; Maes et al. 2008). A behavioural study of pigs with mycoplasmal
pneumonia showed no significant differences in food intake, body temperature or time
spent “active” compared with healthy swine (Escobar et al. 2007). Clinical symptoms,
such as decreased appetite, fever, laboured breathing or exhaustion, are due to
secondary pathogens (Ross, 1986).
Mycoplasmal pneumonia is associated with the sequential development of
microscopic and macroscopic lung lesions (Livingston et al. 1972; Ross, 1986) in the
apical, cardiac, intermediate and the cranial sections of the diaphragmatic lobes
(Sorenson et al. 1997). The lesions typically occur 14-28 days after experimental
infection (Sorenson et al. 1997; Kwon et al. 2002). Microscopically, lymphocytic cuffs
occur around the airways, and there may be hyperplasia of the respiratory epithelium
and occasionally, alveoli. Alveoli and airway lumens contain macrophages, and to a
lesser extent, lymphocytes, neutrophils and plasma cells (Livingston et al. 1972; Ross,
1986; Kwon et al. 2002; Thacker and Minion, 2012). In advanced microscopic lesions,
lymphocytic cuffs are more obvious and may contain lymphoid nodules (Thacker and
Minion, 2012). The submucosal glands in bronchi may be hyperplastic and contain
elevated numbers of goblet cells (Thacker and Minion, 2012). In recovering
microscopic lesions, alveoli are collapsed and/or enlarged, and lymphoid nodules are
common in peribronchial regions (Thacker and Minion, 2012). The gross lesions of
mycoplasmal pneumonia consist of purple to grey areas of consolidation, that when cut
are thick and “meaty” but not overly firm (Thacker, 2006; Thacker and Minion, 2012).
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In recovered macroscopic lesions there are interlobular scar retractions (Maes et al.
2008) and enlargement of regional lymph nodes (Thacker, 2006). Gross lesions
typically resolve 12-14 weeks after a pure M. hyopneumoniae infection (Maes et al.
2008); however, M. hyopneumoniae can persist in lung tissue of experimentally infected
pigs for up to 185 days pi even though there may no longer be any clinical signs of
infection (Fano et al. 2005).

A

B

B

Figure 1.1 Mycoplasmal pneumonia-induced microscopic and macroscopic lung lesions. (A)
Histological examination of lung tissue of pigs infected with M. hyopneumoniae show
peribronchiolar and perivascular lymphocytic hyperplasia and infiltration of macrophages and
neutrophils within airway lumens (arrow). Bar = 95 µm (Sarradell et al. 2003). (B) Dark areas
of consolidation in the apical and cardiac lobes (arrows) consistent with moderate mycoplasmal
pneumonia-induced lung lesions (Lee, 2013).

1.3 Adherence and colonisation by M. hyopneumoniae
Upon inhalation, M. hyopneumoniae must overcome the mucociliary clearance
mechanism and associate with ciliated epithelial cells present in the respiratory tract of
swine. Adherence by M. hyopneumoniae to the ciliated epithelium induces ciliostasis,
loss of cilia and exfoliation of ciliated cells (Livingston et al. 1972) (Figure 1.2).
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D

Figure 1.2 Adherence to epithelial cilia lining the upper respiratory tract of swine is an essential
step in M. hyopneumoniae pathogenesis. (A) Transmission electron micrograph of M.
hyopneumoniae cells (M) adhering to cilia (C) of swine tracheal ring epithelium five days pi.
Bar = 0.83 µm. (DeBey and Ross, 1994). (B) Scanning electron micrographs from a section of
fixed trachea from an uninfected piglet showing normal healthy cilia. Bar = 2 µm. (Blanchard et
al. 1992). (C) Scanning electron micrographs from a section of fixed trachea from a M.
hyopneumoniae-infected piglet two weeks pi showing M. hyopneumoniae adhering to cilia. Bar
= 1 µm. (Blanchard et al. 1992). (D) Scanning electron micrographs from a section of fixed
trachea from a M. hyopneumoniae-infected piglet eight weeks pi showing extensive loss of cilia
and exfoliation of ciliated cells. Bar = 10 µm. (Blanchard et al. 1992).

The destruction of the mucociliary apparatus leads to a significant reduction in the
clearance of debris and invading pathogens, thereby predisposing the host to secondary
infections (Livingston et al. 1972 Blanchard et al. 1992; DeBey and Ross, 1994;
Sorensen et al. 1997; Thacker, 2006). The mechanism(s) which trigger cilial damage are
unknown; however, adherence of pathogenic M. hyopneumoniae to cilia stimulates an
intracellular calcium release from the endoplasmic reticulum of tracheal cells which
may function as an intracellular signal for shedding of cilia (Park et al. 2002). It is
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possible for cilia to regrow following M. hyopneumoniae-infection, as is evident from
transmission electron micrographs of bronchial epithelium from convalescent pigs
(Irigoyen et al. 1998). Although M. hyopneumoniae primarily colonises ciliated
respiratory epithelium it has also been re-isolated from the brain (Friis, 1974), kidney,
lymph nodes (Le Carrou et al. 2006), spleen and liver (Marois et al. 2007) of infected
swine; however, dissemination to distal tissues is transitory and thus is unlikely to
influence the development of mycoplasmal pneumonia (Le Carrou et al. 2006; Marois et
al. 2007).
M. hyopneumoniae does not possess a terminal organelle; an electron dense, rod-like
structure which occurs in a tip region on the cell surface of some bacteria and functions
as the attachment organelle in Mycoplasma species such as Mycoplasma gallisepticum
(Nakane and Miyata, 2009), Mycoplasma genitalium (Mernaugh et al. 1993),
Mycoplasma penetrans (Lo et al. 1993), Mycoplasma pirum (Tham et al. 1994) and
Mycoplasma pneumoniae (Powell et al. 1976). Rather a “fuzzy layer” of delicate fibrils
radiating from the plasma membrane of M. hyopneumoniae cells to host cilia has been
observed by transmission electron microscopy (Figure 1.3A). This layer is alleged to
play a role in adherence of mycoplasma cells to cilia, as is evidenced by its diminished
thickness in non-adherent M. hyopneumoniae strains (Tajima and Yagihashi, 1982;
Zhang et al. 1995), and the presence of an important cilium adhesin, P97, amongst the
fibrils (Zhang et al. 1995; Hsu et al. 1997) (Figure 1.3B). The actual chemical
composition of the layer is unknown; however, ruthenium red staining has revealed the
presence of polyanionic compounds that are most likely to be polysaccharides (Tajima
and Yagihashi, 1982).
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Figure 1.3 Transmission electron micrograph of the fuzzy layer of delicate fibrils which radiate
from the surface of M. hyopneumoniae. (A) Section of the bronchiolar epithelium from a pig
killed 5 days after intranasal inoculation with in vivo passaged M. hyopneumoniae strain MI-3.
The two mycoplasma cells are connected via radiating fibrils (f) present on the bacterial cells.
The fibrils also extend between the mycoplasma cells and host cilia. Bar = 200nm (Tajima and
Yagihashi, 1982). (B) M. hyopneumoniae cells labelled with an anti-P97 monoclonal antibody
(F2G5) and goat anti-mouse IgM conjugated with gold particles. The arrows indicate the
presence of P97 within the fuzzy layer surrounding M. hyopneumoniae cells. Bar = 100 nm
(Zhang et al. 1995).

Microtitre plate cilium binding-assays proved instrumental in identifying potential
receptor-ligand interactions and the nature of the receptors involved in host-pathogen
interactions (Zielinkski and Ross, 1993; Zhang et al. 1994a; Zhang et al. 1995). In these
studies, pre-treatment of cilia with sodium metaperiodate, an inorganic salt which
disrupts carbohydrate structure, significantly reduced binding of M. hyopneumoniae to
cilia (Zhang et al. 1994a). Adherence to cilia was also diminished by pre-incubating
mycoplasma cells with a range of sulphated carbohydrates and glycoconjugates
including heparin, mucin, fucoidan, laminin, chondroitin sulphate A and chondroitin
sulphate B. These results highlight the importance of sulphated carbohydrate chains as
receptors for M. hyopneumoniae; however, the presence of sulphate alone does not
facilitate adherence to cilia, as an assortment of other sulphated compounds were shown
to have no effect on binding interactions. Rather the location of sulphonation within the
carbohydrate chain is important for mediating M. hyopneumoniae-host interactions, as
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is evidenced by the failure of chondroitin sulphate C, a compound that differs
structurally from chondroitin sulphate A only in the position of sulphate on the
carbohydrate chain, to act as an adherence inhibitor (Zhang et al. 1994a). Subsequent
thin-layer chromatography overlay assays demonstrated that the receptor analogs
identified by Zhang et al. (1994a) also inhibited binding of M. hyopneumoniae to three
sulphated glycolipids, designated La, Lb and Lc, that were extracted from porcine cilia
and indentified as the native receptors for the association of mycoplasmas with the
ciliated respiratory epithelium (Zhang et al. 1994b).
The identification of monoclonal antibodies F2G5 and F1B6, which inhibit adherence
of mycoplasma to porcine cilia by 62% and 67% respectively (Zhang et al. 1995), was
crucial for characterising the first M. hyopneumoniae cilium adhesin; a 97 kDa surface
protein designated P97 (Zhang et al. 1995; Hsu and Minion, 1998b). Located within the
carboxyl terminus of P97 are two proline-rich repetitive domains designated R1 and R2
(Hsu et al. 1997). R1 comprises tandem pentapeptide repeats of the sequence A(T)A(T)-K-P-E(V), while R2 comprises tandem decapeptide repeats of the sequence GA(E,S,T)-P-N(S)-Q-G-K-K-A-E (Hsu et al. 1997). The number of copies of R1 and R2
vary amongst M. hyopneumoniae strains; ranging from 2-21 repeats of R1 and 2-6
repeats of R2 (Wilton et al. 1998; Stakenborg et al. 2005). Interestingly R1 and R2 are
not homologous to repeats found in other Mycoplasma species (Hsu et al. 1997);
however, they bear striking homology with domains found in porcine collage type VI
(α3 isoform 5) and porcine ribosomal binding protein 1 (also known as KIAA1398)
respectively (Deutscher et al. 2010). Whilst the biological significance of the repeat
regions sharing homology with porcine protein sequences is unknown, it may signify
molecular mimicry of host proteins, or represent domains for M. hyopneumoniae
association with different eukaryotic proteins (Wanker et al. 1995; Dallo et al. 1996;
Ogawa-Goto et al. 2002, 2007; Deutscher et al. 2010). Transposon mutagenesis of P97
and an in vitro microtitre plate-adherence assay identified R1 as the cilium binding
region of P97 (Hsu and Minion, 1998a), with a minimum of eight R1 units required for
cilial binding (Minion et al. 2000). Despite the significance of the R1 repeat region in
P97, attachment to epithelial cilia by M. hyopneumoniae is a multifactorial process that
involves an array of cilium adhesins, including but not limited to, members of the
P97/P102 paralog family (Adams et al. 2005; Burnett et al. 2006; Wilton et al. 2009;
Deutscher et al. 2010, 2012; Seymour et al. 2010, 2011, 2012; Bogema et al. 2011,
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2012), of which only three possess R1 (Hsu et al. 1997; Deutscher et al. 2010, 2012)
suggesting that unidentified cilium binding domains must occur within the other
paralogs.

1.4 The P97/P102 paralog family
The genes encoding P97 (mhp183) and P102 (mhp182) are located in a two-gene
operon (Hsu and Minion, 1998b). Genome sequencing of pathogenic M.
hyopneumoniae strain 232 identified six P97 paralogs (Mhp107, Mhp271, Mhp280,
Mhp385, Mhp493 (P216) and Mhp684) and six P102 paralogs (Mhp108 (P116),
Mhp272, Mhp274, Mhp275, Mhp384 and Mhp683) (Figure 1.4); where a paralog was
defined as a protein for which it’s amino acid sequence shared greater than 30% identity
over 70% of its length (Minion et al. 2004). Notably, the genes encoding P216 and the
glycoprotein Mhp494 (P159) also form a two gene structure; however, P159 does not
classify as a P102 paralog according to the definition outlined by Minion et al. (2004),
but nonetheless shares a low level of sequence homology with this protein (Burnett et
al. 2006). For ease of discussion, P159 will be referred to as a P102 paralog family
member throughout this thesis.

Figure 1.4 The P97/P102 paralog family members and genome location. The P97 paralogs are
shown in black and the P102 paralogs are shown in grey. The genes encoding two paralogs,
Mhp280 and Mhp493, are not shown as they do not occur with a P102 paralog. Arrows indicate
direction of transcription (Adams et al. 2005).
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With the exception of mhp280, the genes encoding all P97/P102 paralog family
members are transcribed during infection, and all gene pairs except mhp107 and
mhp108 produce single messenger ribonucleic acid (mRNA) transcripts, suggesting
they are functionally analogous (Adams et al. 2005). Furthermore, the deduced amino
acid sequences for the P97 and P102 paralog families in three M. hyopneumoniae
genomes (pathogenic strains 232 and 7448, and non-pathogenic strain J) share greater
than 94% identity between each paralog (Ferreira and de Castro, 2007).
The P97/P102 paralog family members are targeted by M. hyopneumoniae proteases
to generate an array of cell-associated cleavage fragments which have been
hypothesised to allow M. hyopneumoniae to modify its surface architecture and avoid
host immune responses (Djordjevic et al. 2004; Burnett et al. 2006; Jenkins et al. 2006;
Wilton et al. 2009; Deutscher et al. 2010, 2012; Seymour et al. 2010, 2011, 2012;
Bogema et al. 2011, 2012). Endoproteolytic cleavage of the P97/P102 paralogs often
occurs at an S/T-X-F↓X-D/E-like site (Bogema et al. 2011); however, not all processing
conforms to this cleavage motif and indicates the involvement of multiple proteases
(Djordjevic et al. 2004; Deutscher et al. 2012). Interestingly, M. hyopneumoniae
proteins other than the P97/P102 paralogs have not been shown to undergo proteolytic
cleavage (Djordjevic et al. 2004; Wilton et al. 2009). Given that mycoplasmas possess a
minimal set of genes (Vasconcelos et al. 2005), and that a suite of combinatorial surface
proteins can be generated by endoproteolytic cleavage events, these observations
suggest that the P97/P102 paralogs play an important role in M. hyopneumoniae
pathogenesis. Certainly extensive characterisation of the paralogs, undertaken with
recombinant fragments spanning the full length proteins, have found them to be
multifactorial adhesins which exploit host surface glycoconjugates and extracellular
matrix components including heparin, fibronectin and plasminogen to a likely end of
facilitating M. hyopneumoniae colonisation and the establishment of chronic infection
(Zhang et al. 1995; Djordjevic et al. 2004; Burnett et al. 2006; Jenkins et al. 2006;
Wilton et al. 2009; Deutscher et al. 2010, 2012; Seymour et al. 2010, 2011, 2012;
Bogema et al. 2011, 2012).
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1.4.1 Heparin and its interaction with members of the P97/P102 paralog family
Heparin is a negatively charged, highly acidic polysaccharide found in the
intracellular granules of mast cells lining the arteries of the lungs, skin and liver (Patti et
al. 1994; Rostand and Esko, 1997; Dubreuil et al. 2002). Heparin is structurally similar
to the extracellular matrix component cell-adhesion molecule heparan sulphate in that
both possess a backbone of iduronate residues (Dubreuil et al. 2002). Heparan sulphates
are found along the entire surface of the porcine respiratory tract (Erlinger, 1995);
however, limited commercial supplies necessitate the use of heparin as an analogous
model for adherence-based assays (Montemurro et al. 2002; Rabenstein, 2002). Heparin
and heparan sulphates act as bridging molecules, mediating interactions between
numerous extracellular matrix components, including fibronectin, laminin, vitronectin
and collagen, as well as factors involved in inflammation and immunomodulation
(Conrad 1998; Islam and Linhardt, 2003). Binding is typically mediated by electrostatic
interactions between the highly negative sulphate groups of heparin and basic amino
acid residues, namely lysine and arginine; however, polar amino acids such as
glutamine and asparagine also contribute (Sobel et al. 1992).
Microtitre plate-adherence assays and surface plasmon resonance have shown that
several recombinant fragments of the P97/P102 paralog family of proteins, including
F1-F2P97 (Jenkins et al. 2006), F1-F3385 (Deutscher et al. 2012), F2-F3384 (Deutscher et
al. 2012), F2271 (Deutscher et al. 2010), F3-F4P159 (Burnett et al. 2006), F1-F3P216
(Wilton et al. 2009), F1Mhp107 (Seymour et al. 2011), F1P146 and F3P146 (Bogema et al.
2012) and F1-F5683 (Bogema et al. 2011) bind heparin in a dose-dependent and
saturable manner. Competitive binding assays revealed the interaction of the
recombinant fragments with biotinylated heparin was inhibited in the presence of
unlabelled heparin, and was therefore mediated by specific binding sites (Burnett et al.
2006; Wilton et al. 2009; Deutscher et al. 2010, 2012; Bogema et al. 2011, 2012).
Whilst the heparin binding domains within these recombinant fragments have not been
accurately defined, several of the protein sequences are rich in arginine and/or lysine
residues which are expected to contribute to binding (Burnett et al. 2006; Deutscher et
al. 2010; Bogema et al. 2011). Furthermore, denatured F1-F3P216 displays reduced
heparin binding activity, suggesting protein conformation may also be necessary to
efficiently bind heparin (Wilton et al. 2009). The degree of sulphation, as well as the
Page | 13

location of sulphate functional groups can also influence heparin-protein binding
interactions (Rabenstein, 2002). This is the case for the association of F1-F2P97 (Jenkins
et al. 2006), F2385, F2-F3384 (Deutscher et al. 2012), F2271 (Deutscher et al. 2010), F3F4P159 (Burnett et al. 2006), F1-F3P216 (Wilton et al. 2009), F1P146, F3P146 (Bogema et al.
2012), and F1-F5683 (Bogema et al. 2011) with heparin, which can be inhibited in the
presence of excess levels of fucoidan (a highly sulphated polysaccharide with a
branched, comb-like structure) but not chondroitin sulphate B (which is structurally
similar to heparin) (Burnett et al. 2006). Mucin, a highly sulphated compound found in
mucosal secretions (van Nieuw Amerongen et al. 2004), was also shown to be a strong
competitor for F1-F2P97 (Jenkins et al. 2006), F1-F3P216 (Wilton et al. 2009), F1-F3683
and F5683 (Bogema et al. 2011) in competitive-binding assays.
Heparan sulphates bound to the cell-surface of M. hyopneumoniae may facilitate
direct attachment to epithelial cilia lining the porcine respiratory tract as well as the
indirect recruitment of other glycosaminoglycan-binding host molecules to promote
adherence to or invasion of host cells (Zhang et al. 1994; Burnett et al. 2006; Jenkins et
al. 2006; Wilton et al. 2009; Deutscher et al. 2010, 2012; Bogema et al. 2011; Seymour
et al. 2011; Bogema et al. 2012). Consequently, as heparin-binding proteins P97,
Mhp385, Mhp384, Mhp271, P159, P216, Mhp107, P146 and P135 are likely to play an
important role in M. hyopneumoniae pathogenesis.

1.4.2 Fibronectin and its interaction with members of the P97/P102 paralog family
Fibronectin is a 440 kDa glycoprotein that is extensively distributed in a soluble form
in plasma, body fluids and inflammatory exudates (Mosher, 1984), and as an insoluble
form in the extracellular matrix or on the surface of cells (McKeown-Longo, 1987).
There are at least 20 isotypes of soluble fibronectin owing to alternative, posttranslation splicing events of its two constituent subunits (Hynes, 1990; Aumailley and
Gayraud, 1998; Pankov and Yamada, 2002). The subunits, connected via a pair of Cterminal disulphide bonds (Hynes and Yamada, 1982), are primarily composed of three
types of repetitive units, designated Type I, Type II and Type III, which are organised in
a linear array (Hynes, 1985) and are separated by short hinge regions that enable the
molecule to assume different conformations (Johansson et al. 1997). The repeating units
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are arranged into functional domains which bind fibronectin, fibrin, collagen, heparin,
gelatine and numerous cell surface integrins (Proctor, 1987; Potts and Campbell, 1994).
These functional domains impart on fibronectin a remarkably wide variety of biological
activities including cell adhesion, migration and differentiation, cytoskeletal
rearrangement, wound healing, chemotaxis, phagocytosis, neovascularisation and
embryogenesis (Mosher, 1984).
In vitro binding assays have shown that the R2 repeat region of P97 (Seymour et al.
2011) and rP102 (Seymour et al. 2012), as well as several recombinant fragments of the
P97/P102 paralog family of proteins, including rP42 (Seymour et al. 2012), F2271
(Deutscher et al. 2010), F4P116 (Seymour et al. 2010) and F3Mhp107 (Seymour et al. 2011)
bind fibronectin at physiologically relevant concentrations. Further studies are required
to identify the fibronectin-binding motif within the recombinant fragments (Seymour et
al. 2010). Recruitment of fibronectin to the cell surface may facilitate M.
hyopneumoniae-host cell interactions, as well as the dissemination of M.
hyopneumoniae within the host to the brain, kidney, lymph nodes, spleen and liver
(Deutscher et al. 2010; Seymour et al. 2010, 2011, 2012). Furthermore, surface-bound
fibronectin may assist M. hyopneumoniae in establishing chronic infection (Seymour et
al. 2012), particularly since this glycoprotein is present in increased concentrations
during the repair of damaged lung tissue (Coraux et al. 2008). Thus, as fibronectinbinding proteins P102, Mhp271, P116 and Mhp107 are likely to play an important role
in M. hyopneumoniae pathogenesis.

1.4.3 Plasmin(ogen) and its interaction with members of the P97/P102 paralog family
Plasminogen, the zymogen precursor of the serine protease plasmin, is found
circulating in plasma at high concentrations (Lähteenmäki et al. 2001), and is also
distributed throughout lung tissue and in the extracellular fluid lining the porcine
respiratory tract where it is readily available to M. hyopneumoniae during colonisation
(Seymour et al. 2012). Tissue-type plasminogen activator (tPA) and urokinase-type
plasminogen activator (uPA) are host proteases which convert plasminogen into
plasmin via cleavage of the Arg561-Val562 peptide bond (Robbins et al. 1967; Petersen et
al. 1990). This action produces an N-terminal heavy chain that contains a hydrophobic
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lysine binding cleft which mediates attachment to lysine-containing receptors, fibrin and
the extracellular matrix, as well as a C-terminal light chain that contains the catalytic
serine protease domain (Ponting et al. 1992; Lähteenmäki et al. 2001). Binding of
plasminogen to lysine-containing receptors induces the zymogen precursor to assume a
more open conformation, and concurrently increases plasminogen activation (Claeys
and Vermylen, 1974) and protects plasmin from inactivation by its lysine-dependent
inhibitors (Lähteenmäki et al. 2001). In the host, plasmin(ogen) is a component of the
fibrinolytic system, contributing to wound healing and tissue repair through the
breakdown of fibrin clots (Matsuoka et al. 2006; Degen et al. 2007). Plasmin is also
involved in hydrolysing extracellular matrix and basement membrane components,
including fibronectin, laminin, vitronectin, collagen and proteoglycans (Rifkin et al.
1997; Dubreuil et al. 2002; Pancholi et al. 2003), and therefore contributes to a plethora
of biological processes related to cell adhesion and migration (Swaisgood et al. 2007;
Gong et al. 2008; Wygrecka et al. 2009). Of particular importance to this study is the
role of plasmin as an inflammatory cell activator and a potent stimulus of proinflammatory cytokine expression (Syrovets et al. 2012). M. hyopneumoniae infection is
characterised by chronic airway inflammation (Kobisch and Friis, 1996; Sarradell et al.
2003; Redondo et al. 2009), with various pulmonary pathologies purportedly associated
with elevated secretion of pro-inflammatory cytokines including interleukin (IL)-1, IL-6
and tumor necrosis factor (TNF)-α (Redondo et al. 2009) (see section 1.5).
Macrophages and monocytes play a central role in the inflammatory process during
chronic diseases such as atherosclerosis and rheumatoid arthritis, and express on their
surface the annexin A2 heterotetramer (Hansson, 2005; Laumonnier et al. 2006; Li et al.
2010); a subunit of which binds plasminogen and its inhibitors (MacLeod et al. 2003).
Upon activation, bound plasmin stimulates in macrophages and monocytes the mitogenactivated protein kinase (MAPK) and nuclear factor kappa B (NK-κB)-dependent
expression of pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α and/or
prostaglandin E2 (PGE2) (Syrovets et al. 2001; Burysek et al. 2002; Li et al. 2010).
Plasmin also induces the accumulation of monocytes and dendritic cells at the site of
inflammation by eliciting chemotatic protein kinase C and guanosine monophosphate
(Syrovets et al. 1997) or activating the Ak2-dependent pathway respectively (Li et al.
2010). Consequently, plasmin plays an important role in the host immune response
against infectious organisms; however, excessive activation of plasmin during chronic
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inflammatory diseases may exacerbate the pathogenesis of the disease (Syrovets et al.
2012).
Microtitre-adherence based assays and surface plasmon resonance have shown that
the R2 repeat region of P97 (Seymour et al. 2011), and rP102 (Seymour et al. 2012), as
well as several recombinant fragments of the P97/P102 paralog family of proteins,
including rP60, rP42 (Seymour et al. 2012), F4P116 (Seymour et al. 2010), F1Mhp107
(Seymour et al. 2011) and F3P146 (Bogema et al. 2012) bind plasminogen in a dosedependent and saturable manner. Deletion of the C-terminal lysine residues from rP102,
rP42 (Seymour et al 2012) and F3P146J, or the C-terminal arginine residue from F3P146232
(Bogema et al. 2012) reduced the level of binding observed by the recombinant
fragments, demonstrating the significance of these residues in the affinity for
plasminogen. However, other residues must also mediate the interaction of M.
hyopneumoniae with plasminogen as a C-terminal lysine or arginine does not occur in
rP60 (Seymour et al. 2012). Alternatively internal lysines may be responsible for
plasminogen-binding in proteins which lack this residue at their C-terminus (Cork et al.
2009; Bogema et al. 2012).
M. hyopneumoniae is unable to directly activate surface-bound plasminogen;
however, recruitment of plasminogen to the cell-surface is suggested to enhance the
tPA-mediated activation of bound plasminogen (Seymour et al. 2012), possibly via
inducing a conformational change in the zymogen precursor which increases its
susceptibility to proteolytic cleavage (Lähteenmäki et al. 2001). Activation of
plasminogen at the bacterial cell surface and exploitation of the proteolytic system may
enable M. hyopneumoniae to influence its immediate environment. For instance,
degradation of the extracellular matrix may offer an explanation as to how M.
hyopneumoniae mediates damage to ciliated respiratory epithelium during the diseaseprocess (Blanchard et al. 1992; DeBey and Ross, 1994; Seymour et al. 2012).
Furthermore, degradation of the extracellular matrix of ciliated epithelial cells renders
underlying extracellular matrix components, such as fibronectin, for M. hyopneumoniae
receptor-ligand interactions and may therefore promote bacterial adherence and
invasion of host tissues (Pancholi et al. 2003; Seymour et al. 2012). Consequently, as
plasminogen-binding proteins, P102, P116, Mhp107 and P146 are likely to play an
important role in M. hyopneumoniae pathogenesis.
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1.5 M. hyopneumoniae-host immune system interactions
M. hyopneumoniae survival and proliferation within host tissues as well as the disease
process appears to be dependent upon alteration of the porcine innate and adaptive
immune responses (Messier et al. 1990; Maes et al. 1996; Thacker et al. 2001);
however, the mechanisms by which M. hyopneumoniae induces immunopathologic
modifications remain poorly understood. Lung histopathology associated with
mycoplasmal pneumonia is characterised by the influx of inflammatory cells, mainly
macrophages, dendritic cells, lymphocytes, and IgA- and IgG-containing plasma cells in
the peribronchiolar and adjacent connective tissues (Livingston et al. 1972; Sarradell et
al. 2003). Whilst differentiation of macrophages and related cells of the myeloid lineage
into dendritic cells which phagocytose, process and present antigen for induction of
antigen-specific immune responses represents an important first line of defence in
innate immunity (Bienenstock, 1984; Murtaugh and Foss, 2002; Rodriguez et al. 2004),
M. hyopneumoniae suppresses the phagocytic capacity of pulmonary alveolar
macrophages (Caruso and Ross, 1990), as well as polymorphonuclear neutrophils
(PMNs) (Asai et al. 1996). This action likely renders the host more susceptible to
mycoplasma infection and secondary pathogens (Caruso and Ross, 1990; Asai et al.
1996).
M. hyopneumoniae-infection also stimulates macrophages and monocytes to secrete
various pro-inflammatory and immunoregulatory cytokines including IL-1, IL-2, IL-4,
IL-6, IL-8, IL-10, IL-12, IL-18, TNF-α, interferon (IFN)-γ and PGE2 (Asai et al. 1993,
1994; Thanawongnuwech et al. 2001; Sarradell et al. 2003; Choi et al. 2006; Muneta et
al. 2006; Rodriguez et al. 2007). Although cytokine secretion contributes to the
elimination of invading pathogens by co-ordinating and activating the adaptive immune
response (Van Reeth et al. 2002; Thanawongnuweck and Thacker, 2003; Choi et al.
2006) and regulating numerous cell types including macrophages, neutrophils and T and
B lymphocytes (Asai et al. 1993; Thanawongnuweck et al. 2001; Van Reeth et al.
2002), overproduction can lead to host-mediated tissue injury in the lungs (Choi et al.
2006). In fact, chronic inflammatory responses and lymphoid hyperplasia following M.
hyopneumoniae infection appear to be more responsible for the occurrence of lung
lesions than the organism itself (Thacker, 2006).
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Expression of IL-1 and TNF-α in pneumonic lungs of pigs experimentally infected
with M. hyopneumoniae has been observed to increase from 1 to 3 wpi and decrease
thereafter, suggesting that these cytokines play an important role in the early stages of
disease (Choi et al. 2006). IL-1 and TNF-α are classic pro-inflammatory cytokines that
augment the immune response by inducing expression of adhesion molecules and
stimulating the chemotaxis and activation of phagocytes (Baarsch et al., 1995;
Dinarello, 1992; Lorenzo et al. 2006). High levels of IL-1 are known to stimulate IL-6
production (Lorenzo et al. 2006); offering an explanation for elevated levels of IL-6 in
bronchus-associated lymphoid tissue (BALT) of pigs naturally infected with M.
hyopneumoniae when lesions were at a chronic stage (Rodriguez et al. 2004). In vitro
studies indicate IL-6 acts as an anti-inflammatory cytokine, impeding expression of proinflammatory cytokines such as IL-1 and TNF-α (Dinarello, 1992). IL-1 and TNF-α also
stimulate production of PGE2; a cytokine for which its biological activities affect not
only inflammation but also suppression of various cell functions (Asai et al. 1994).
Elevated levels of IL-8, a pro-inflammatory cytokine that is chemotactic for neutrophils
(Dinarello, 1992), have been detected in the alveolar septa (Lorenzo et al. 2006;
Thanawongnuweck et al. 2001), bronchoalveolar exudate and BALT (Lorenzo et al.
2006) of experimentally infected pigs from 1 wpi. Secretion of IL-8; however, appears
to be negatively associated with the predominance of macrophages and lymphocytes
over neutrophils during the chronic stages of natural infection (Rodriguez et al. 2004;
Lorenzo et al. 2006). IL-2 and IL-4 are consistently expressed in the alveolar septa and
in various mononuclear cells of the bronchoalveolar exudates of experimentallyinfected pigs from 1 wpi (Lorenzo et al. 2006), and have been implicated in the
characteristic lymphoid

hyperplasia associated

with

mycoplasmal

pneumonia

(Livingston et al. 1972; Maes et al. 1996; Sarradell et al. 2003). Additionally elevated
levels of IL-10 have been detected in alveolar septa and bronchoalveolar lavage fluid
(BALF) of M. hyopneumoniae-infected pigs, and showed different kinetics depending
on the pulmonary compartment analysed (Thanawongnuwech and Thacker, 2003;
Lorenzo et al. 2006). IL-10 is produced by T lymphocytes and activated macrophages,
and being an effective inhibitor of pro-inflammatory cytokines and macrophage
function it has been linked with clinical protection and reduced lung lesion severity
(Moore et al. 1993; Morrison et al. 2000). Immunolabelling for IL-12 and IFN-γ has
detected both cytokines in the thickened alveolar septa and in the germinal centres of
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the BALT in the lungs of pigs 7 days post-experimental infection. The number of cells
positive for IL-12 and IFN-γ is greatest at 2 to 3 wpi, and slightly decreases thereafter
(Rodriguez et al. 2006). IL-12 production is thought to be a pre-requisite for stimulating
optimal Th1 responses and cell-mediated immunity by inducing the activation and
proliferation of macrophages in damaged lung tissue (Stern et al. 1996; Murtaugh and
Foss, 2002; Rodriguez et al. 2006). Furthermore, IL-12 induces production of IFN-γ in
resting and activated T lymphocytes (Stern et al. 1996), which in turn has a positive
feedback effect on the generation of IL-12, thereby perpetuating a Th-1 based response
(Murtaugh and Foss, 2002; Thanawongnuweck and Thacker, 2003). The proinflammatory cytokine IL-18 is also secreted during M. hyopneumoniae infection;
however, little is known about its pathophysiological role (Muneta et al. 2006).
In addition to the effects described above, M. hyopneumoniae has a non-specific
mitogenic effect on accumulated lymphocytes in the lungs of infected swine (Messier et
al. 1990; Messier and Ross, 1991). Furthermore, mycoplasmal pneumonia-induced lung
lesions are less prominent in M. hyopneumoniae-infected thymectomised pigs treated
with antibodies against T lymphocytes, suggesting that T-cell dependent immune
responses may be important in lung tissue damage (Tajima et al. 1984). Cytolytic
activity of T lymphocytes is also alleged to play a role in averting the invasion and
dissemination of M. hyopneumoniae, as is evidenced by the isolation of M.
hyopneumoniae from the spleen of thymectomised pigs (Tajima et al. 1984).
Local humoral immunity has been implicated in the recovery of swine from
mycoplasmal pneumonia and resistance to reinfection by M. hyopneumoniae (Sarradell
et al. 2003). Seroconversion in pigs experimentally infected with M. hyopneumoniae
typically occurs between 10 and 21 days (Sheldrake et al. 1990; Lorenzo et al. 2006).
Immunohistological studies of local humoral immune responses in pigs experimentally
infected with M. hyopneumoniae detected elevated levels of IgA-, IgG- and IgMcontaining cells in retropharyngeal and bronchial lymph nodes two weeks after infection
(Suter et al. 1985). In retropharyngeal lymph nodes, the maximum number of
immunoglobulin-containing cells of all isotypes was reached by 3 weeks post-challenge.
Similar results were observed in bronchial lymph nodes, except for IgG-containing cells
which reached maximum values 4 weeks after infection (Suter et al. 1985).
Immunohistological studies have also detected elevated levels of IgA- and IgGPage | 20

containing cells in the BALT, alveolar septa, and bronchial and bronchiolar walls of
pigs naturally infected with M. hyopneumoniae (Saradell et al. 2003). High levels of
immunoglobulin positive cells in the lungs of M. hyopneumoniae infected swine
correlate with reductions in both bacterial load and lung lesion severity (Messier et al.
1990). Secretion of IgA at the site of infection is suggested to prevent adherence of M.
hyopneumoniae to cilia, and IgG could enhance phagocytosis of mycoplasma cells by
alveolar macrophages (Sheldrake, 1990, 1993). Convalescent swine are highly resistant
to reinfection (Kobisch et al. 1993) but become susceptible during the final stages of
pregnancy due to the transferral of antibodies from the blood to the colostrum (Wallgren
et al. 1998). Providing piglets receive a sufficient quantity of antibodies from the
colostral milk, they may be protected from M. hyopneumoniae infection for up to 14
days of age (Rautiainen and Wallgren, 2001; Martelli et al. 2006). Collectively, these
observations provide evidence for the importance of humoral immunity as a protective
agent against mycoplasmal pneumonia.

1.6 Diagnosis of M. hyopneumoniae infection
A tentative diagnosis of M. hyopneumoniae infection is the occurrence of a dry, nonproductive cough (Maes et al. 1996; Sibila et al. 2009). The presence of microscopic
and macroscopic lung lesions lends support to a diagnosis, and the prevalence of M.
hyopneumoniae within a herd may be assessed by scoring the proportion of lung
affected with pneumonia at necropsy (Hannan et al. 1982; Morrison et al. 1985; Straw
et al. 1986; Christensen et al. 1999). However, neither microscopic nor macroscopic
lung lesions are specific for mycoplasmal pneumonia, and infection by other respiratory
pathogens complicates accurate diagnosis (Thacker, 2004). Furthermore, gross lesions
may have resolved by the time of market sale and thus the incidence of M.
hyopneumoniae within a herd may be missed if periodic necropsy of swine with clinical
signs is not performed (Sibila et al. 2009; Thacker and Minion, 2012). Definitive
diagnosis of mycoplasmal pneumonia requires the isolation of M. hyopneumoniae from
infected lung tissue; however, culturing is painstakingly slow, requires a specialised
media that contains M. hyopneumoniae-negative swine serum (Friis, 1974) and is often
prone to overgrowth by other porcine respiratory mycoplasmas such as M. flocculare
and M. hyorhinis (Maes et al. 1996; Thacker, 2004). Serology is commonly used to
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establish the presence of M. hyopneumoniae within a herd, with various commercial
enzyme-linked immunosorbent assays (ELISAs) available for detection of mycoplasma
serum antibodies (Djordjevic et al. 1994; Thacker, 2004). There are however several
complications associated with serological diagnosis of M. hyopneumoniae including:
variations in seroconversion (Thacker, 2004); discrepancies in the ability of the
commercial ELISAs to detect antibodies raised in pigs experimentally challenged with
different M. hyopneumoniae field isolates (Vicca et al. 2002; Strait et al. 2008);
increased levels of M. hyopneumoniae antibodies associated with concurrent infection
with PRRSV (Thacker et al. 1999), porcine circovirus 2 (Opriessnig et al. 2004) or
swine influenza virus (Thacker et al. 2001); vaccination regime (Erlandson et al. 2005;
Thacker et al. 1998, 2000); and cross-reactivity with M. flocculare antibodies (Bereiter
et al. 1990). The presence of M. hyopneumoniae in the lung tissue can be confirmed
either by fluorescent antibody (FA) or immunohistochemistry (IHC) assays (Amanfu et
al. 1984; Opriessnig et al. 2004), or in situ hybridisation (Kwon and Chae, 1999).
Whilst these assays are quick and cheap, tissues must include airways with ciliated
epithelial cells and be fixed (IHC and ISH) or frozen (FA) so as to prevent postmortem
degradation (Thacker, 2004). Polymerase chain reaction (PCR) assays have improved
the accuracy of M. hyopneumoniae detection and can be applied to various collection
sites, though the most useful samples are lung tissue and bronchial washings (Sorensen
et al. 1997; Calsamiglia et al. 1999; Calsamiglia and Pijoan, 2000; Kurth et al. 2002;
Dubosson et al. 2004; Stakenborg et al. 2006; Strait et al. 2008; Fablet et al. 2010;
Marois et al. 2010). Furthermore, PCR assays which simultaneously target several
genes have been developed and overcome issues attributed to genetic variability among
M. hyopneumoniae field isolates (Marois et al. 2010; Strait et al. 2008). Given the
sensitivity of PCR assays, there is the possibility of contamination during collection or
testing (Thacker, 2004) and thus positive results should be confirmed in multiple
samples or by using a combination of diagnostic technologies (Thacker and Minion,
2012).
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1.7 Current treatments and prevention of M. hyopneumoniae infection
M. hyopneumoniae infection can be controlled through husbandry management
practices, biosecurity measures, antibiotic therapy and vaccination (Maes et al., 2008).
Initial implementation of management strategies such as all-in, all-out production (Clark
et al., 1991), parity segregation (Joo, 2003), appropriate animal stocking densities
(Pointon et al., 1985; Madec, 1984) and piggery design is paramount to controlling
transmission of M. hyopneumoniae (Maes et al., 2008).
Treatment of mycoplasmal pneumonia is often through antimicrobial medication.
Macrolides and tetracyclines are the most commonly used antimicrobials (Maes et al.,
2008) and offer partial protection against clinical signs and pneumonic lesions (Ciprian
et al., 2012); β-lactam antibiotics such as ampicillin and penicillin are ineffective as M.
hyopneumoniae lacks a cell wall (Thacker et al., 2006). Strategic medication regimes
whereby antimicrobials are administered for a limited time prior to the expected onset
of disease can result in pneumonia outbreaks after cessation of the therapy (Thacker and
Minion, 2010). Alternatively, antibiotics may be provided intermittently throughout
production (Le Grand and Kobisch, 1996). Whilst antimicrobial resistance is currently
not a major concern in the control of M. hyopneumoniae infection (Maes et al., 2008),
acquired bacterial resistance to tetracyclines (Inamoto et al., 1994) and macrolides
(Vicca et al., 2004) has been reported. Thus prolonged or continuous medication during
production should be avoided to limit increased antimicrobial resistance and the risk of
antibiotic residues in animal products.
Vaccination with commercial inactivated whole-cell preparations (bacterins) is a
widely used practice for controlling M. hyopneumoniae infection; more than 70% of pig
herds in many countries are vaccinated against M. hyopneumoniae (Maes et al., 2008).
Numerous studies have been conducted on the effects of vaccination on pig productivity
with several demonstrating that vaccination can improve average daily weight gain in
infected herds due to better overall health and improved feed efficiency (Jenson et al.,
2002; Maes et al., 2003; Moreau et al., 2004). Furthermore, administration of
commercial bacterins can significantly reduce clinical signs and lung lesion severity
(Maes et al., 1999; Baccaro et al., 2006) and may reduce bacterial load in the respiratory
tract of swine (Meyns et al., 2006; Villarreal et al., 2011). The exact mechanisms by
which M. hyopneumoniae bacterins elicit a partially protective immune response are
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unknown. Intramuscular administration of commercial bacterins has been shown to
induce mucosal and systemic M. hyopneumoniae-specific antibody responses, as well as
the secretion of IFN-γ, IL-10- and IL-12 in the blood, bronchial lymph nodes and/or
lung tissue of pigs (Thacker et al. 2000; Marchioro et al. 2013). Vaccination also
appears to regulate the secretion of IL-β, IL-6 (Marchioro et al. 2013) and TNF-α
(Thacker et al. 2000) into BALF. Collectively these studies suggest that both humoral
and cellular immunity are important for protection; however, the role of systemic
humoral immunity remains unclear as no direct correlation has been found between
serum antibody concentration and protection against mycoplasmal pneumonia
(Djordjevic et al. 1997; Thacker et al. 1998).
The protective efficacy of commercial bacterins can vary between herds and may be
affected by several factors including: improper storage and administration of the
vaccine (Maes et al. 2008); antigenic heterogeneity between M. hyopneumoniae field
isolates and vaccine strains (Calus et al. 2007); differences in the virulence status of M.
hyopneumoniae isolates (Vicca et al. 2003); and pig health status at the time of
vaccination (Thacker et al. 2000). Another major pitfall with the current commercial
bacterins is their failure to prevent colonisation by M. hyopneumoniae (Thacker et al.,
2000). Furthermore, production of M. hyopneumoniae bacterins is labour intensive and
costly (Moreau et al. 2004); hence the development of alternative vaccine strategies is
justified.

1.8 Experimental M. hyopneumoniae vaccines
The search for an effective vaccine for mycoplasmal pneumonia began with
inactivated vaccines prepared from M. hyopneumoniae whole cell extracts; however, the
whole cell extracts offered no protection against M. hyopneumoniae infection unless
they were combined with Freud’s complete adjuvant or a mixture of Bayol/Arlacel
adjuvants, in which case adverse reactions rendered their use unacceptable (Goodwin
and Whittlestone, 1973). Formalin-killed M. hyopneumoniae cells mixed with an
alternative adjuvant (Auspharm) and delivered via the intraperitoneal route was
subsequently shown to reduce the severity of pneumonic lung lesions, without the
adverse effects associated with earlier formulations (Sheldrake et al. 1991). Ross et al.
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(1984) illustrated the protective efficacy of a culture supernatant vaccine; however,
Okada et al. (2000a) suggested that the presence of whole cells or membranes may have
contributed to this protection, since the centrifugation used in the preparation of the
supernatant vaccine did not remove all of the mycoplasma cells or membranes. Okada et
al. (2000a) therefore examined the protective efficacy of inactivated vaccines prepared
from sedimented whole cells and cell-free culture supernatants. Whilst the sedimented
whole cell vaccines offered variable protection, and in some instances exacerbated the
development of gross lung lesions, a significant reduction in the proportion of affected
lung was observed in pigs inoculated with the culture supernatant vaccine (Okada et al.
2000a). Later studies into lung pathology and the cytology of BALF from pigs
immunised with the cell-free culture supernatant suggested the observed reduction in
lung lesion severity was associated with a decrease in the total number of inflammatory
cells in the BALF of vaccinated pigs (Okada et al. 2000b). Isolation of M.
hyopneumoniae from the lungs of pigs vaccinated with the culture supernatant indicated
that the vaccine was unable to prevent colonisation of the host (Okada et al. 2000b). An
oral microencapsulated vaccine based on the PRIT-5 M. hyopneumoniae strain and
prepared by a co-spray drying method also offered partial protection against
mycoplasmal pneumonia; the formulation reduced the severity of lung lesions and
induced significant mucosal and systemic humoral immune responses (Lin et al. 2003).
Similarly a significant reduction in lung damage associated with mycoplasmal
pneumonia was demonstrated in a trial by Djordjevic et al (1997) in which a cocktail of
denatured M. hyopneumoniae membrane proteins (ranging in size from 75-85 kDa) was
formulated with a selection of adjuvants and delivered intramuscularly or
intraperitoneally.
The complexity of the media required for cultivation of M. hyopneumoniae and related
expenses for producing whole cell or culture supernatant vaccines makes the use of
recombinant technologies an economically viable alternative for developing a vaccine
against mycoplasmal pneumonia (Conceicao et al. 2006). Numerous studies have
evaluated vaccines comprising recombinant proteins of M. hyopneumoniae delivered
independently (King et al. 1997; Galli et al. 2012, 2013; Simionatto et al. 2012), as a
cocktail (Chen et al. 2008; Galli et al. 2013), coupled with viral or bacterial vectors
(Fagan et al. 1997, 2001; Chen et al. 2001, 2006a, b; Shimoji et al. 2003; Ogawa et al.
2009; Okamba et al. 2007, 2010; Zou et al. 2011) or fused to mucosal adjuvants
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(Conceicao et al. 2006). Typically the vaccine candidate in these studies was the cilium
adhesin P97; however, others were trialled including P102, Mhp272 (Galli et al. 2013),
the R2 subunit of ribonucleotide reductase (NrdF) (Fagan et al. 1997, 2001; Chen et al.
2006), P42 heat shock protein (Chen et al. 2003; Galli et al. 2012), P37-like ABC
transporter substrate binding lipoprotein (Galli et al. 2012), the L-lactate dehydrogenase
gene (p36) (Zou et al. 2011), membrane proteins P42 (Chen et al. 2003; Galli et al.
2012) and P95 (Galli et al. 2012), as well as numerous uncharacterised, hypothetical
proteins (Simonatto et al. 2012; Galli et al. 2013). Immunogenicity of these antigens has
been evaluated in both mice (Table 1.2) and pigs (Table 1.3). Differences in the immune
responses stimulated by these antigens were observed, with factors such as the vaccine
candidate construct, immunisation route and regime as well as the correct folding and/or
other posttranslational modifications having likely contributed to the degree by which
these formulations were immunogenic (Pinto et al. 2007). Only a select few studies
have investigated immunogenicity of recombinant subunit vaccines in challenge
experiments in swine (King et al. 1997; Fagan et al. 2001; Ogawa et al. 2009; Okamba
et al. 2010) (Table 1.3); an important strategy given that immune responses elicited by a
vaccine are species-specific and induction of M. hyopneumoniae-specific antibodies in
mice does not correlate with protection in pigs (Galli et al. 2013).
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Table 1.2 Overview of the immunogenicity of M. hyopneumoniae recombinant subunit vaccines
after oral, intramuscular (IM), intranasal (IN) or subcutaneous (SC) inoculation of mice.
Vaccination stimulated significanta:

Antigen
[adjuvant/vector]

Route

IgA

IgG

Cellular
immunity

NrdF (R2)

Oral

+

-

ND

Reference

Cytokines
b

ND

Fagan et al.
(1997)

[S. typhimurium aroA SL3261]
NrdF (R2)

Oral

+

-

+

ND

Fagan et al.
(2001)

[S. typhimurium aroA SL3261]
P42

IM

ND

+

+

IFN-γ, IL-2,

Chen et al.

IL-4 (↑)

(2003)

ND

Shimoji et al.

[pcDNA3]
P97 (R1R2)

IN

-

-

+

(2003)
[E. rhusiopathiae YS-1]
P97 (R1)

Oral

-

-

ND

IFN-γ (↑)

Chen et al.
(2006a)

[S. typhimurium aroA CS332]
NrdF (R2)

Oral

-

-

IFN-γ (↑)c

Chen et al.
(2006b)

[S.typhimurium aroA CS332]
P97 (R1)

IM

+

+

ND

-

[LTB]

IN

+

+

ND

IFN-γ (↑)

P97 (R1)

IM

-

+

ND

ND

[Adenovirus]

IN

+

+

ND

ND

P97, P97R1, NrdF, P36, P46

IM

ND

+d

ND

IFN-γe (↑)

[pcDNA3.1 and/or Aluminium]

SC

ND

+

ND

IFN-γ (↑)

Conceicao et al.
(2006)

Okamba et al.
(2007)

Chen et al.
(2008)
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P36

IM

ND

+

ND

Zou et al.

ND

(2011)
[A. pleuropneumoniae SLW36]
34 uncharacterised proteins

IM

ND

+

ND

Simionatto et al.

ND

(2012)
[Aluminium]
P37, P42, P46, P95

IM

ND

+

ND

IL-1, TNF-α
f

(↓) , IFN-γ
[Aluminium or pcDNA3]
a

Galli et al.
(2012)

(↑)

Significant immune response in vaccinated mice compared with unvaccinated control group;

b

As

c

determined by the proliferation of antigen-specific mononuclear cells in the spleen. IFN-γ response was
elicited by S. typhimurium aroA CS332 carrying the eukaryotic recombinant plasmid encoding NrdF but
not by S. typhimurium aroA CS332 carrying the prokaryotic recombinant plasmid encoding NrdF; d The
only significant serum IgG response detected in mice immunised with the DNA cocktail was against P46;
e

Mice immunised with the DNA cocktail produced significant levels of specific IFN-γ against all

antigens except NrdF;

f

The relative expression of TNF-α was higher in mice immunised with

pCDNA3/P42 and pCDNA2/P95 relative to control mice. Salmonella typhimurium: S.typhimurium;
Erysipelothrix rhusiopathiae: E. rhusiopathiae; Actinobacillus pleuropneumoniae: A. Pleuropneumoniae;
ND: Not determined; ↑: elevated cytokine response compared with unvaccinated control group; ↓:
repressed cytokine response compared with unvaccinated control group.

The first recombinant subunit vaccine to be evaluated in a challenge experiment in
swine was composed of glutathione S-transferase (GST)-tagged P97, and was
administered twice intramuscularly to pigs that were then inoculated intratracheally with
M. hyopneumoniae strain 232 (King et al. 1997). Vaccination induced antigen-specific
serum IgG responses, and whilst clinical signs of mycoplasmal pneumonia were
reduced, no statistically significant difference was detected compared with the control
groups. The potential role of P97 as a vaccine candidate was not ruled out since delivery
of the challenge inoculum deep into the trachea may have been inappropriate as it would
have bypassed the region of the upper respiratory tract where P97 facilitates
mycoplasmal adherence to host cell, and to where protective immunity against the
antigen may have been raised (King et al. 1997).
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Table 1.3 Overview of the immunogenicity of M. hyopneumoniae recombinant subunit vaccines
after oral, intramuscular (IM), intranasal (IN) or subcutaneous (SC) inoculation of swine.
Antigen

Route

Vaccination stimulated significanta:

Challenge

Reference

infection
[adjuvant/vector]

IgA

IgG

Cellular

Cytokines
b

immunity
P97

IM

+

ND

+

ND

ND

King et al.
(1997)

[Freund’s complete
adjuvant]
P97 (R1)

SC

-

ND

+

ND

ND

Chen et al.
(2001)

[Pseudomonas
exotoxin A]
NrdF (R2)

Oral

+

+

-

+

ND

Fagan et al.
(2001)

[S. typhimurium
aroA SL3261]
P97 (R1R2)

IN

-

-

-

+

ND

Shimoji et
al. (2003)

[E. rhusiopathiae
YS-1]
P97 (R1R2)

Oral

+

+

+

ND

ND

Ogawa et al.
(2009)

[E. rhusiopathiae
Koganei]
P97

IN

+

+

+

+c

TNF-α, IL-1β,
d

IL-6 (↑) IL-8
[Adenovirus]
a

Okamba
et al. (2010)

(↓)

Significant immune response in vaccinated swine compared with unvaccinated control group;

b

As

determined by the proliferation of antigen-specific peripheral blood mononuclear cells (PBMC) or
antigen-specific mononuclear cells in the spleen;

c

A PBMC proliferation response was detected after

d

vaccination, but levels declined post-challenge; Elevated cytokine response in vaccinated compared with
unvaccinated pigs; however, no statistically significant difference between the two groups was detected;
ND: Not determined; ↑: elevated cytokine response compared with unvaccinated control group; ↓:
repressed cytokine response compared with unvaccinated control group.
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An attenuated strain of Salmonella typhimurium aroA SL3261 expressing a
recombinant protein containing the C-terminal of NrdF (SL3261 (pKF1)) was evaluated
as a live oral vaccine against mycoplasmal pneumonia (Fagan et al. 2001). Pigs were
inoculated twice with SL3261 (pKF1) and challenged with M. hyopneumoniae.
Vaccination primed the immune system to induce significant NrdF-specific IgA and
IgG responses, and stimulated the proliferation of blood lymphocytes. Reduced lung
pathology was also observed in the vaccinated pigs compared with the control groups.
Collectively these results demonstrate the potential of NrdF to be a promising
component in a vaccine for mycoplasmal pneumonia (Fagan et al. 2001).
In another recombinant vector vaccine study, Ogawa et al. (2009) constructed an
attenuated Erysipelothrix rhusiopathiae Koganei 65-0.15 strain expressing the Cterminal domain of P97. Delivery of the recombinant E. rhusiopathiae strain in milk
replacer to pigs on three consecutive days not only protected pigs from erysipelas but
induced significant P97-specific IgA and IgG responses in animals subsequently
challenged with M. hyopneumoniae. Furthermore, pneumonic lesions were significantly
reduced in vaccinated pigs compared with the control animals; however, mycoplasma
load in the BALF did not vary between the two groups, indicating that the vaccine was
unable to prevent colonisation by M. hyopneumoniae.
The potential use of a P97 recombinant replication-defective adenovirus (rAdP97c)
subunit vaccine for protection against M. hyopneumoniae infection in swine was
evaluated by Okamba et al. (2010) and compared with a commercial bacterin. In this
study rAdP97c was administered twice by the intranasal route and pigs were inoculated
intratracheally with M. hyopneumoniae strain 232. rAdP97c vaccinates had significantly
elevated anti-P97 specific IgA and IgG responses in sera and saliva post-vaccination
and after challenge. The rAdP97c vaccine induced proliferation of peripheral blood
mononuclear cells (PBMC), although this response declined after challenge, possibly
due to immunoregulation by the host or as a direct effect of M. hyopneumoniae.
Furthermore, bacterial load was significantly reduced in the lungs and BALF of
rAdP97c vaccinates, with sera from these pigs having an inhibitory effect on the growth
of mycoplasma cells in vitro. Nonetheless, immunisation with a commercial-bacterin
based vaccine was shown to evoke superior protection against mycoplasmal pneumonia
compared with the rADP97c vaccine, even though it failed to induce a P97 specific
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immune response. Okamba et al. (2010) therefore concluded that immunodominant
antigens other than P97 are likely to be important for generating protective immunity.

1.8.1 The P97/P102 paralog family members as potentially protective antigens
against M. hyopneumoniae infection
Adherence to ciliated respiratory epithelium is an essential step in M. hyopneumoniae
pathogenesis and is facilitated by receptor-ligand interactions. Among the likely
adhesins are those belonging to the P97/P102 paralog family. Members of this family
are targets of endoproteolytic cleavage events, generating an array of multifunctional
fragments that remain associated with the surface of M. hyopneumoniae cells
(Djordjevic et al. 2004; Burnett et al. 2006; Jenkins et al. 2006; Wilton et al. 2009;
Deutscher et al. 2010; Bogema et al. 2011, 2012; Seymour et al. 2011, 2012) (Table
1.4). The P97 and P102 paralogs are well conserved amongst geographically diverse M.
hyopneumoniae isolates (Burnett et al. 2006; Wilton et al. 2009; Deutscher et al. 2010;
Bogema et al. 2011, 2012; Seymour et al. 2011, 2012), and with the exception of
mhp280 are all transcribed in vivo (Adams et al. 2005) (Table 1.4). Furthermore being
surface exposed the paralogs are potential targets of the swine humoral immune
response. Indeed, P97 (Minion et al. 2000), P159 (Burnett et al. Thesis), P216 (Wilton
et al. 2009) and P135 (Bogema et al. 2011) are recognised by convalescent serum from
pigs naturally infected with M. hyopneumoniae (Table 1.4). Collectively these findings
demonstrate the important role that the P97/P102 paralog family of proteins have in M.
hyopneumoniae pathogenesis, and highlight their potential as good targets for vaccine
development.
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Table 1.4 Summary of the information currently available on characterised P97/P102 paralog
family members. Data presented in this table is taken from the results of multiple studies as
referenced in text.
Surface accessible adhesin binds:
Cilia

Heparin

Fibronectin

Plasminogen

Conserved

Transcribed

Recognised

among

in vivo

by

Mhp

convalescing

isolates

pig serum

P97

+

+

+

+

+

+

+

P102

+

ND

+

+

+

+

ND

Mhp385

+

+

ND

-

+

+

ND

Mhp384

+

+

ND

-

+

+

ND

Mhp271

+

+

+

-

+

+

ND

P159

+

+

ND

ND

+

+

+

P216

+

+

ND

ND

+

+

+

P116

+

ND

+

+

+

+

ND

Mhp107

+

+

+

+

+

+

-

P146

+

+

ND

+

+

+

ND

P135

+

+

ND

ND

+

+

+

Of the paralogs, only P97 has been investigated as a potential protective antigen
against mycoplasmal pneumonia, and whilst it has been shown to be immunogenic in
both mice (Table 1.2) and pigs (Table 1.3), recombinant vaccines containing this protein
alone offer only partial protection against M. hyopneumoniae infection and subsequent
development of pneumonic lesions (King et al. 1997; Ogawa et al. 2009; Okamba et al.
2010). Given that vaccination with a single antigen has only rarely been found to offer
protection against a given disease (Altmann and Mukkur, 1983; Greenwood et al. 1988;
Adkins and Wagstaff, 1998) perhaps simultaneous administration of multiple P97/P102
paralogs (i.e. a multivalent vaccine) could provide better protection against M.
hyopneumoniae infection (Chen et al. 2008; Galli et al. 2013).
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1.9 Aims of this study
The aims of this study were to evaluate recombinant subunit vaccines for protection
against the colonisation of swine by M. hyopneumoniae, and to investigate
inflammatory responses during the early stages of mycoplasmal pneumonia in pigs
following experimental challenge. The specific objectives of this study were:
1)

To evaluate clinical, histological and immunological changes and qPCR
detection of M. hyopneumoniae in tissues during the early stages of
mycoplasmal pneumonia in pigs after experimental challenge with two
Australian M. hyopneumoniae field isolates (Hillcrest and Beaufort), and to
determine which of the two strains would be a suitable challenge strain for
use in a subsequent vaccine trial.

2)

To evaluate recombinant subunit vaccines containing fragments of eight
multifunctional adhesins of the M. hyopneumoniae P97/P102 paralog family
formulated with selected adjuvants as vaccines against experimentallyinduced mycoplasmal pneumonia in pigs.

3)

To determine whether plasmin activity in the porcine respiratory tract plays
a role in the host response to M. hyopneumoniae infection and investigate
whether vaccination with a commercial bacterin had a corresponding effect
on this activity.
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Chapter 2: General Methods
2.1 Bacterial strains, plasmids and culture
2.1 M. hyopneumoniae
The M. hyopneumoniae strains used in this study (Hillcrest, Beaufort and 232) were
obtained from various sources as described previously (Scarman et al. 1997; Seymour et
al. 2011), and were cultured in modified Friis medium (Appendix) on a rotary shaker at
37˚C as detailed by Scarman et al. (1997). M. hyopneumoniae cells were harvested at
mid-log phase, when the medium had changed from a red to honey-yellow colour (pH
6.8-7.2). Mycoplasma cells were pelleted by centrifugation for 30 min at 10,000 × g
(Sorvall RC5C Plus; GSA Rotor) and washed twice in phosphate-buffered saline (PBS;
Appendix).

2.2 E. coli
E. coli strains used in this study are listed in Table 2.1. E. coli strains were grown at
37˚C in Luria Bertani (LB) broth (Appendix) or on LB agar (Appendix) (Sambrook et
al. 1989) supplemented with ampicillin at 100 µg/mL and/or kanamycin at 50 µg/mL.
Liquid cultures were aerated at 250 rpm.

2.2 Cloning, protein expression and purification
2.2.1 Plasmin DNA extraction and purification
Extraction and purification of plasmid DNA from E. coli was typically performed using
the Wizard® Plus SV Minipreps DNA Purification System (Promega, USA) according
to the manufacturer’s instructions.

Page | 34

Table 2.1 E. coli strains used in this study.
Strain/Plasmid
Use
Strain
E. coli TOP10
Plasmid maintenance strain
E. coli BL21™ Star
Expression strain for recombinant 6×His(DE3)
tagged or GST-tagged proteins
Plasmid
pGEX-2T
GST-tagged protein expression
Recombinant plasmid
6× His-tagged F2P97 protein expression
pQE-9:f2P97
pET151/D:rP102
6× His-tagged rP102 protein expression
pQE-9:f4P159
6× His-tagged F4P159 protein expression
pET161:f3P216
6× His-tagged F3P216 protein expression
6× His-tagged F3P116 protein expression
pET151/D: f3P116
pET100/GW/D:f1P146
6× His-tagged F1P146 protein expression
6× His-tagged F3P135 protein expression
pET161/GW/D:f3P135
pET161/GW/D:f4P135
6× His-tagged F3P135 protein expression
GST-tagged F2P97 protein expression
pGEX-2T:f2P97
pGEX-2T:rP102
GST-tagged rP102 protein expression
pGEX-2T:f4P159
GST-tagged F4P159 protein expression
pGEX-2T:f3P216
GST-tagged F3P216 protein expression
pGEX-2T: f3P116
GST-tagged F3P116 protein expression
pGEX-2T:f3P135
GST-tagged F3P135 protein expression
pGEX-2T:f4P135
GST-tagged F4P135 protein expression
6×His: hexahistidine; GST: glutathione-S-transferase.

Source
Invitrogen™ (USA)
Invitrogen™ (USA)

Smith and Johnson (1988)
Jenkins et al. (2006)
Seymour et al. (2012)
Burnett et al. (2006)
Wilton et al. (2009)
Seymour et al. (2010)
Bogema et al. (2012)
Bogema et al. (2011)
Bogema et al. (2011)
This study
This study
This study
This study
This study
This study
This study

2.2.2 PCR amplification
Primers incorporating BamHI and EcoRI restriction sites were designed (see chapter
4, Table 4.1) to enable directional cloning of gene fragments encoding F2P97, rP102,
F4P159, F3P216, F3P116, F3P135 and F4P135 into the pGEX-2T vector. In M. hyopneumoniae,
UGA codons encode tryptophan rather than a stop codon, thus necessitating mutation of
all in-frame UGA codons to UGG. Consequently, PCR products in this study were
amplified from plasmid DNA extracted from previously mutagenised constructs (see
Table 2.1) rather than from M. hyopneumoniae genomic DNA. PCR amplification was
performed with the proofreading DNA polymerase Pfu (Stratagene, USA) in 50 µL
reactions containing 150-200 ng of plasmid DNA, 1× PCR buffer (supplied with the
polymerase and containing MgCl2), 0.2 mM deoxynucleotide triphosphates (dNTPs;
Boehringer Mannheim, Germany), 400 nM of each primer and 1 U of Pfu DNA
polymerase. Thermal cycling was performed with a CP2-01 Thermal Cycler (Corbett
Research, Australia) and Palm-Cycler™ Version 2.2 software (Corbett Research,
Page | 35

Australia). Typical cycling conditions were as follows: initial denaturation at 94˚C for 5
min (1 cycle); denaturation at 94˚C for 1 min (25 cycles); annealing at 50˚C for 1 min
(25 cycles); extension at 72˚C for 1 min (25 cycles); and a final extension at 72˚C for 7
min (1 cycle).

2.2.3 Agarose gel electrophoresis and gel excision
Prepared agarose gels, 1% (w/v) molecular-grade agarose (Bio-Rad, USA) in 0.5×
Tris-borate ethylenediamine tetraacetic acid buffer (TBE Buffer; Appendix), were
transferred to a Bio-Rad MiniSub™ or Wide MiniSub™ electrophoresis chamber (BioRad, USA) and overlaid with 0.5× TBE buffer. DNA samples containing 2 µL of
loading dye (Appendix) were loaded into gel wells and electrophoresed, alongside
Fermentas GeneRuler™ 100 bp DNA Ladder Plus, at a constant voltage of 90 V for 1 h
using a Bio-Rad PowerPac 300. DNA was stained using ethidium bromide and
visualised under UV light using a Gel Doc™ 1000 fluorescent imaging system (BioRad, USA) and Quantity One® software (Bio-Rad, USA). For molecular cloning the
PCR product was excised from the agarose gel using a sterile scalpel blade, and purified
using the Wizard® SV Gel and PCR Clean-Up System (Promega, USA) according to the
manufacturer’s instruction.

2.2.4 Cloning of PCR amplification products into the pGEX-2T expression vector
Purified PCR products were digested with BamHI and/or EcoRI, and ligated with
BamHI and/or EcoRI digested, dephosphorylated pGEX-2T vector according to the
manufacturer’s instructions (GE Healthcare, USA). The ligation mixture was then used
to transform electro-competent E. coli TOP10 cells (Invitrogen, USA) according to the
manufacturer’s instructions. Briefly, plasmid DNA (1 µL) was pipetted into a vial of
electro-competent E. coli TOP10 cells, mixed gently and transferred into a sterile
chilled 0.2 cm Gene Pulser®/E. coli Pulser™ Cuvette (Bio-Rad, USA). A Bio-Rad Gene
Pulser® (Bio-Rad, USA), set at a voltage of 2.5 kV, a capacitance of 25 µF and a
resistance of 200 Ω, was used to deliver a single pulse with a time constant between 4
and 5 ms. Transformed cells were immediately resuspended in 500 µL of pre-warmed
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(37˚C) LB broth, transferred to a sterile 5 mL tube and incubated at 37˚C with shaking
(200 rpm) for 1 h before being plated onto selective agar. To screen for positive
transformants, LB broth (5 mL) supplemented with appropriate antibiotics, was
inoculated with randomly selected transformants and incubated overnight at 37˚C with
horizontal shaking at 250 rpm. Plasmid DNA extracted from transformed E. coli
according to section 2.2.1 was screened by PCR using the insert primers and cycling
parameters outlined in section 2.2.2. The PCR master mix was modified by substituting
Pfu DNA polymerase with Taq DNA polymerase (Roche, Switzerland). Positive
transformant plasmids were sequenced by the Australian Genome Research Facility
(AGRF), Australia.

2.2.5 Recombinant protein expression
Plasmid DNA (2 µL) containing the desired insert was transformed into chemicallycompetent E. coli BL21™ Star (DE3) cells (Invitrogen, USA) according to the
manufacturer’s instructions. The entire transformation mixture was inoculated into 100
mL of pre-warmed LB broth, supplemented with appropriate antibiotics, and incubated
overnight at 37˚C with shaking (250 rpm). The overnight culture was diluted into 900
mL of pre-warmed selective LB broth and grown at 37˚C until an OD600nm of 0.5-0.8
was reached (typically 1-2 h). A 1 mL aliquot of the culture, representing a non-induced
control in sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis (PAGE),
was collected. Cells were induced with isopropyl-β-D-thiogalactopyranoside (IPTG),
added at a final concentration of 1 mM or 0.1 mM for the expression of 6×His- or GSTtagged proteins respectively. After a 4 h induction at 37˚C, a 1 mL sample of the culture
was collected for an induced-control in SDS-PAGE. Bacterial cells were harvested by
centrifugation for 30 min at 10,000 × g at 4˚C.

2.2.6 Purification of recombinant 6×His-tagged proteins by nickel-affinity
chromatography under denaturing conditions
Cleared lysates of recombinant 6×His-tagged proteins were prepared under
denaturing conditions using Buffer B according to the protocol described in the
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QIAexpressionist™ manual (Qiagen, USA). Harvested cells were thawed at room
temperature for 15 min, resuspended in 40 mL of Buffer B (Appendix) and lysed for 1 h
at room temperature with gentle stirring. Cellular debris was removed from the lysate
by centrifugation for 30 min at 10,000 × g at 4˚C (Sorvall RC5C Plus; GSA Rotor). The
cleared lysate was added to 6 mL of nickel-nitrilotriacetic acid (Ni-NTA) superflow
resin (Qiagen, USA) and incubated at room temperature for 30 min with gentle stirring.
The lysate-resin mixture was then applied to the column, and allowed to settle. Flow
through was collected and proteins that bound non-specifically to the Ni-NTA resin
were washed from the column in 20 mL of Buffer C (Appendix; 4 × 5 mL fractions
collected). Bound recombinant proteins were eluted in 10 mL of Buffer D (Appendix;
10 × 1 mL fractions collected) followed by 10 mL of Buffer E (Appendix; 10 × 1 mL
fractions collected) and stored at 4˚C prior to analysis by SDS-PAGE. Fractions
containing the protein of interest were pooled and dialysed against 1× PBS (see section
2.2.8).

2.2.7 Purification of recombinant GST-tagged proteins on a glutathione-agarose
column under native conditions
Cleared lysates of recombinant GST-tagged proteins were prepared under native
conditions according to the protocol described in the GST Gene Fusion Manual (GE
Healthcare). Harvested cells were thawed on ice and resuspended in ice-cold 1× PBS
containing 1% (v/v) Triton X-100 (45 mL). Five millilitres of ice-cold native lysis
buffer (Appendix) was added to the cell suspension, which was then sonicated. Lysed
cells were centrifuged for 10 min at 12,000 × g at 4˚C (Sorvall RC5C Plus; GSA Rotor)
and the cleared lysate was applied to a column containing glutathione-agarose (Bioline,
Australia). Flow through was collected and the lysate was again applied to the column.
This process was repeated for a total of four times. Un-bound proteins were washed
from the column with 50 mL of 1× PBS. Bound recombinant proteins were eluted in 20
mL of glutathione elution buffer (Appendix) stored at 4˚C prior to analysis by SDSPAGE. Fractions containing the protein of interest were pooled and dialysed against 1×
PBS (see section 2.2.8).
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2.2.8 Dialysis of recombinant proteins
Fractions containing the recombinant protein of interest, as determined by SDSPAGE analysis were pooled, transferred to SnakeSkin™ Pleated Dialysis Tubing 3.5kDa MWCO (Pierce, USA) and dialysed against 2 L of 4 M urea. The urea in the
dialysis solution was gradually reduced to 0.5 M urea during buffer changes so as to
minimise the precipitation of protein. If the protein precipitated, 0.01% SDS/1× PBS
(w/v) was added to the final buffer change to re-solubilise the protein. Dialysis was
performed over a minimum of 24 h, with constant stirring and regular buffer changes
(refreshed after a minimum of 2 h) to ensure removal of urea from protein samples.

2.2.9 Protein quantification and concentration
Concentrations of the dialysed proteins were determined using the Bicinchoninic
Acid (BCA) protein assay kit according to the manufacturer’s instructions. Proteins
were concentrated using an Amicon® Ultra-4 centrifugal filter unit (10 kDa molecular
mass cut-off) (Millipore, Germany) according to the manufacturer’s instructions.

2.3 SDS-PAGE
SDS-PAGE analysis was performed using the Mini-PROTEAN® series system (BioRad, USA), a 12% polyacrylamide resolving gel (Appendix) and a 4% polyacrylamide
stacking gel (Appendix). Whole-cell lysates collected from non-induced and induced
expression cultures were prepared for SDS-PAGE analysis by centrifugation for 5 min
at 13,000 rpm at room temperature. Whole cell lysates, as well as fractions collected
during recombinant protein purification were boiled in 1× Cracking buffer (Appendix)
for 5 min. Samples were loaded into gel wells alongside 10 µL of PageRuler™ Protein
Ladder marker (Fermentas, Lithuania) or PageRuler™ Prestained Protein Ladder
(Fermentas, Lithuania). Polyacrylamide gels were run for 45 min in 1× SDS-PAGE
Buffer (Appendix) using a PowerPac 300 power supply (Bio-Rad, USA) set at a
constant voltage of 200 V. Following electrophoresis, the resolving gel was removed
from the stacking gel and transferred to a tray. Protein bands were visualised using
GelCode Blue Coomassie stain (Thermo-Scientific) according to the manufacturer’s
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instructions. Gels were imaged using a GS-800™ calibrated densitometer (Bio-Rad,
USA) and PDQuest™ software (Bio-Rad, USA).
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Chapter 3: Evaluation of clinical, histological and immunological
changes and qPCR detection of Mycoplasma hyopneumoniae in tissues
during the early stages of mycoplasmal pneumonia in pigs after
experimental challenge with two field isolates
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3.1 Abstract
Differences in M. hyopneumoniae strain virulence and infection patterns will affect
experimental challenge systems used to evaluate vaccine efficacy. Two strains (Hillcrest
and Beaufort) were assessed by experimental pig challenge for their ability to induce
clinical and pathological lesions and cytokine responses. TBLF was collected before
and 17-18 days after challenge with Hillcrest (n = 8), Beaufort (n = 8) or no organisms
(n = 3). Coughing was assessed twice daily, and at slaughter 21 (n = 9) or 28 (n = 10)
days post-challenge, gross and histopathology of lungs were quantified and a mhp183
qPCR was applied to detect M. hyopneumoniae DNA in tissues and TBLF. Hillcrest
was clearly superior to Beaufort in its ability to induce coughing and pneumonic
lesions. At 17-18 days, IL-1β and IL-6 concentrations in TBLF were only significantly
higher (8.7 and 5.1 fold respectively) than controls (P<0.001) in Hillcrest-challenged
pigs. Lungs of all Hillcrest-challenged pigs were qPCR positive at either slaughter date,
but only at day 28 in Beaufort-challenged pigs. M. hyopneumoniae DNA was highest in
concentration in lungs 21 days after Hillcrest challenge, and was detected in the spleen,
kidney and/or liver of Hillcrest-challenged pigs, but not in Beaufort pigs. While M.
hyopneumoniae DNA concentration in TBLF was elevated following Hillcrest and
Beaufort challenge, there was no significant difference in mean mycoplasmal DNA
concentration detected in TBLF from pigs challenged with either isolate (P>0.05). Thus
a suitable challenge strain, coupled with lung pathology and cytokine assays, are
valuable in assessing post-challenge responses. Assessment of M. hyopneumoniae DNA
in lung and abdominal tissues by mhp183 qPCR, in conjunction with histopathology,
were valuable in confirming M. hyopneumoniae infection.
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3.2 Introduction
M. hyopneumoniae is the causal agent of mycoplasmal pneumonia, a contagious
pulmonary disease of swine characterised by a dry, non-productive cough, reduced
growth rate and poor feed conversion efficiency (Thacker, 2006). Factors such as
management practices, housing conditions, secondary infections and the use of
antimicrobials and commercial bacterin-based vaccines can influence the severity of
mycoplasmal respiratory disease in pig herds (Maes et al. 2008). However, the virulence
status of M. hyopneumoniae isolates may also affect the clinical pattern of infection, and
thus the protective efficacy of vaccination may vary depending on the virulence of the
strain causing infection (Vicca et al. 2003).
Experimental challenge systems for M. hyopneumoniae are essential for assessing
vaccine efficacy. In most infection models, pigs are typically euthanased at 4 wpi when
clinical signs and lung pathology are thought to be at a peak (Sorensen et al. 1997). This
time-frame may, however, be unsuitable for monitoring clinical symptoms in pigs
challenged with less virulent M. hyopneumoniae strains where lung lesions may not
fully develop until 4 to 8 wpi (Villarreal et al. 2009).
In this study, two field strains of M. hyopneumoniae (Hillcrest and Beaufort) were
compared for their ability to induce mycoplasmal pneumonia. The optimum time to
slaughter pigs for confirmation of infection was investigated by combining clinical
observations with pathologic and histopathologic examination of tissue samples from
challenged pigs necropsied at 21 and 28 days post-challenge. Correlation between two
cytokines (IL-1β and IL-6) thought to play an important role in the early stages of
infection (Choi et al. 2006), and the development of pneumonic lesions at 3 wpi was
also compared for pigs challenged with either isolate. Finally, detection and
quantification of M. hyopneumoniae DNA in lung and abdominal tissues and in TBLF
from necropsied pigs was determined by qPCR.
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3.3 Materials and methods
3.3.1 Bacterial strains and culture conditions
The source of M. hyopneumoniae strains Hillcrest and Beaufort has been described
(Scarman et al. 1997; Seymour et al. 2011). Both are Australian field strains. The
Hillcrest strain was isolated in our laboratory in 2003 from a pig in a New South Wales
commercial herd with gross evidence of pneumonia at slaughter; the Beaufort strain was
originally isolated from a naturally infected pig in Victoria and used in experimental
challenge studies in 1979 (Etheridge et al. 1979). Both strains were retained in Friis
medium at -80ºC at passage levels of approximately 7 (Hillcrest) and 15 (Beaufort)
prior to use in this study. M. hyopneumoniae strains were grown in Friis medium and
cultured as described previously (Scarman et al. 1997).

3.3.2 Pigs and housing conditions
All animal procedures were approved by the Elizabeth Macarthur Agricultural
Institute Animal Ethics Committee in accordance with the Australian Code of Practice
for the Care and Use of Animals for Scientific Purposes. Nineteen male weaner pigs
(predominantly Large White × Landrace, 8-9 weeks old) were obtained from a
commercial herd considered M. hyopneumoniae free on the basis of long-term clinical
and slaughter history, and assigned to three treatment groups balanced by mean weight
(range 15-17 kg per pig per treatment pen) (Table 3.1). Challenged pigs were housed in
groups of four in an experimental piggery with open rung pens, stockboard kennels, and
half concrete-slatted flooring with a rubber mesh overlay. Heating was supplied with
infrared lamps, and external adjustable blinds were also used to reduce draughts. Pigs
had ad libitum access via Maximat feeders (SkioldEchberg A/S, Denmark) to a
commercial pelleted diet (13.7 MJ digestible energy/kg) free of antibiotics. To avoid
cross-contamination due to a limited number of available rooms equipped with
appropriate air filters at the time of this study, the experiments were staggered over time
so that initially, Hillcrest strain was applied to pigs in two treatment pens. A control
unchallenged pig was retained in the same airspace in a pen 20 metres distant from the
Hillcrest-challenged pigs. When these groups had been terminated, the facilities were
cleaned and disinfected. After a 4 week period, new treatment groups for the Beaufort
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strain were introduced. At that time, two control group animals were also introduced
and housed in a separate, temperature controlled (22-24˚C) facility with slatted concrete
flooring 1 km distant, and fed ad libitum with the same diet as the challenged animals.
All movements were controlled so that staff examined control unchallenged animals
before infected animals, and separate protective equipment remained at each separate
site.

Table 3.1 Experimental design for pigs challenged at 9-10 weeks of age.
Group (challenge strain)

No. of pigs necropsied on:

Total

Day 21

Day 28

Hillcrest

4

4

8

Beaufort

4

4

8

Control (Nil)

1

2

3

3.3.3 Collection of TBLF and delivery of challenge inocula
At 9-10 weeks of age, pigs were anaesthetised intravenously with a mixture of
xylazine (Ilium Xylazil®, Troy Laboratories, Smithfield NSW; 1 mg/kg) and ketamine
(Ketamil®, Troy Laboratories, Smithfield NSW; 10 mg/kg), and placed in sternal
recumbency. Approximately 4 ml of PBS was instilled into the trachea twice, and
immediately aspirated under vacuum after each inoculation of PBS, yielding a total of
approximately 6 mL of TBLF. Pigs were then inoculated endotracheally with 10 mL of
M. hyopneumoniae strain Hillcrest or Beaufort cultured in Friis medium. The challenge
inoculum for each strain was determined by dilution studies in 96 well plates (Freundt
and Erno, 1979) to contain 1-2 × 1013 colour changing units per mL. Ten milliliters of
Friis medium containing no M. hyopneumoniae was administered endotracheally to
anaesthetised pigs in the control group. TBLF was again collected at 17-18 days postchallenge, and pigs were euthanased 21 or 28 days post-challenge (Table 3.1). The
controls were euthanased at day 21 (Hillcrest control) or 28 (Beaufort controls).

Page | 45

3.3.4 Clinical evaluation
Pigs were monitored twice daily for a minimum of 15 min for clinical signs of illness,
and observations were recorded on a scale of 0 (normal), 1 (mild abnormal) or 2 (severe
abnormal) for general health, mobility, appetite and coughing at each inspection. The
cumulative (total) coughing scores were calculated for each pig and a mean score per
inspection was also determined. Pigs were weighed 3 days prior to challenge and again
at 21 and 28 days post-challenge.

3.3.5 Pathologic examination
At necropsy, the lungs were removed and evaluated for macroscopic lesions and
scored using the Goodwin lung scoring system (Goodwin et al. 1969). In addition, the
percentage of affected lung was calculated by weighing all grossly consolidated lesions
and comparing with the weight of the entire lung. Samples of liver, spleen, kidney, and
from right and left lung (affected where applicable) were aseptically collected for
mhp183 qPCR. Portions of the lung samples were collected into 10% neutral buffered
formalin for histopathology. Tissue samples for qPCR were stored at -80˚C until
required. Tissue samples for histopathology were examined for peribronchiolar and
perivascular lymphoid cuffing and other changes consistent with M. hyopneumoniaeinduced pneumonic lesions (Taylor, 1996).

3.3.6 Cytokine responses in TBLF
TBLF was centrifuged at 3,000 × g for 10 min to remove cellular debris/mucus and
the supernatant was stored at -80˚C until analysis. Porcine Quantikine® ELISA kits
(R&D, Bio-Scientific Pty. Ltd, Australia) were used, according to the manufacturer’s
instructions, to determine IL-1β and IL-6 responses in the lavage fluid. Plates were read
with an xMark™ Microplate Spectrophotometer (Bio-Rad). Serial dilutions of
reconstituted IL-1β (0-2500 pg/mL) and IL-6 (0-1200 pg/mL) supplied with the
Quantikine kits were used to generate standard curves and establish cytokine
concentrations.
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3.3.7 mhp183 qPCR assay
A previously described qPCR assay (Strait et al. 2008) was used to detect and
quantify mycoplasmal DNA in liver, spleen, kidney, and right and left lung samples and
TBLF. DNA was extracted using the DNeasy Blood & Tissue kit (Qiagen) and
quantified using a NanoDrop™ 1000 Spectrophotometer (Thermo Scientific) according
to the manufacturer’s instructions. As per the DNeasy protocol, tissue amounts of 25 mg
were extracted for liver, kidney and lung samples, and 10 mg for spleen samples. DNA
was similarly extracted from 100 µL volumes of TBLF supernatants. The qPCR assay
was modified by substituting the published universal PCR master mix with VetmaxPlus™ qPCR mastermix (Applied Biosystems) in reaction mixtures containing 100 nM
forward primer (5’-CCAGAACCAAATTCCTTCGCTG-3’), 900nM reverse primer
(5’ACTGGCTGAACTTCATCTGGGCTA-3’),

100

nM

probe

(5’-FAM-

AGCAGATCTTAGTCAAAGTGCCCGTG-BHQ_1-3’), 5 µL of DNA and nucleasefree water to a final volume of 25 µL. Genomic DNA extracted from M.
hyopneumoniae strain Hillcrest (0.0001-10 ng) (extracted using InstaGene Matrix, BioRad) was used to generate a standard curve and quantify DNA in the tissue samples. If
the concentration in the samples was determined by the cycle threshold (CT) value to be
outside the range of standards (i.e.> 100ng/µL) then the sample was diluted 1:25 in
nuclease-free water, and the assay was repeated; the final DNA concentration was then
determined by adjusting for this dilution. Reactions containing cocktail only or
nuclease-free water instead of DNA were used as negative controls. The qPCR assays
were performed with a 7500 Fast Real-Time PCR System (Applied Biosystems) and the
following cycling parameters: 50ºC for 2 min; 95ºC for 10 min; and 40 cycles of 95ºC
for 15 s, and 60ºC for 1 min.
Histopathology on right and left lung samples from Hillcrest- and Beaufortchallenged pigs was used to attribute disease presence or absence in determining a CT
cutpoint for the qPCR assay. Lung samples were assigned a histopathology score on a
scale from 0 (normal lung) to 4 (pneumonic lung consistent with enzootic pneumonia)
(Table 3.2), where scores of 2, 3 and 4 were classified as evidence of mycoplasmal
pneumonia. Histopathology scores for each pig were plotted against CT values, and an
optimal CT cutpoint for the identification of qPCR-positive and -negative samples was
established.
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Table 3.2 Histopathology scoring system of lung sections for mycoplasmal pneumonia.
Peribronchiolar

Bronchiolar

Perivascular

Alveolar

lymphoid

lumen

lymphoid

content

response

content

response

0

Nil

Normal

Nil

Normal

Negative

1

Occasional

Normal

Occasional

Normal

Negative/doubtful

Variable cuffing

Normal or some

Positive (mild)

some prominent

(nil to mild or

MN,

cuffing

moderate)

macrophages,

Score

nodules or

Interpretation

cuffing

cuffing
2

Moderate or

Normal

fluid
3

Moderate to

Normal or

Moderate to

MN and

Positive

marked cuffing

some MN;

marked cuffing

macrophages

(moderate)

possible low

usually present;

numbers of

possibly fluid

PMN or only
evident in
some
4

Marked cuffing

PMN and MN
evident

Marked cuffing

Some PMN,

Positive (marked)

plus MN,
macrophages,
possibly fluid

MN: mononuclear inflammatory cells; PMN: polymorphonuclear neutrophils.

3.3.8 Statistical analyses
Analysis of variance was used to compare the effects of challenge strain on coughing,
average daily weight gain, severity of pneumonic lesions and cytokine responses. Prior
to analysis, data for coughing scores, percentage affected lung by weight, Goodwin lung
scores (GLSs) and IL-6 concentrations in TBLF were transformed (by taking the square
root of coughing scores and log10 of the percentage affected lung by weight, GLSs and
IL-6 concentrations) to reduce variance heterogeneity in diagnostic variables. Data for
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IL-1β concentrations in TBLF did not require transformation since this diagnostic
variable had a probability distribution in which the mean was related to variance. Split
plot analysis of variance was used to compare replicate results of CT values and DNA
concentrations in qPCR analyses of TBLF between challenge strains at 3 weeks postchallenge, and simple linear correlation was used to test correlations between these
values and lung lesion severity. Linear correlations between the mean M.
hyopneumoniae DNA concentrations in lung and abdominal tissue samples in
individuals were examined assuming a non-normal distribution in Spearman’s rank
order correlation test. Results were considered significantly different at P-values < 0.05.

3.4 Results
3.4.1 Clinical disease
Dry, non-productive coughing typical of M. hyopneumoniae infection was observed
in all Hillcrest-challenged pigs and began 8 days post-challenge, continuing throughout
the trial with total coughing scores in the range of 4-13 up to 21 days and up to 18 in the
remaining pigs by 28 days post-challenge. In contrast, coughing was observed in only
three of the Beaufort challenged-pigs, with total scores in the range of 0-1 up to 21 days
and up to 5 in the remaining pigs by 28 days post-challenge and onset of coughing was
delayed until 19 days pi. Over the course of the trial, mean coughing scores per
inspection were 0.213 and 0.003 for all Hillcrest and Beaufort-challenged pigs
respectively to 21 days and 0.266 and 0.007 respectively for Hillcrest and Beaufortchallenged pigs that were retained until 28 days post-challenge. On particular days, the
mean coughing scores ranged from 0-1.33 and 0-0.75 per inspection for Hillcrest and
Beaufort challenged pigs respectively (Figure 3.1). Analysis of the respiratory data
indicated that pigs challenged with Hillcrest had significantly higher coughing scores
than Beaufort challenged pigs (P<0.001). No coughing was observed for pigs in the
negative control group.
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Figure 3.1 Temporal mean coughing scores among treatment groups (Hillcrest, Beaufort,
Control) from 1 to 28 days pi, based on twice-daily recording of individuals on a scale of 0
(normal), 1 (mild abnormal) or 2 (severe abnormal).

There was a statistically significant difference in average daily weight gain between
pigs inoculated with Hillcrest and Beaufort strains of M. hyopneumoniae or Friis
medium over the course of the trial (P<0.05). As expected, pigs in the control group had
the highest average daily weight gain; 0.768 ± 0.070 kg. The lowest average daily
weight gain was 0.602 ± 0.128 kg and occurred for Beaufort-challenged pigs. This was
unexpected given Hillcrest-challenged pigs, which had more severe clinical respiratory
disease, gained an average 0.735 ± 0.154 kg a day, but a secondary infection in one of
the Beaufort challenged pigs possibly skewed average daily weight gain in this group
(data not shown).

3.4.2 Macroscopic lesions
The mean percentage of affected lung tissue typical of mycoplasma-induced lesions
(dark red-to-purple areas of consolidation) and GLSs are summarised in Table 3.3.
Lesions consistent with M. hyopneumoniae pneumonia were observed in Hillcrest and
Beaufort inoculated pigs at 21 and 28 days post-challenge, and a significant correlation
(P<0.0001; r = 0.96) was found between GLS and the percentage affected lung in the
log-transformed data from 13 pigs with gross lung lesions. On day 21, lesions were
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located in the right apical, right cardiac, left apical and/or accessory lobes of Hillcrest
and Beaufort challenged pigs. At 28 days, lesions were also found in some challenged
pigs in the ventro-cranial aspect of the left and right diaphragmatic lobes. The mean
percentages of lung exhibiting macroscopic lesions and mean lesion scores increased
with time for Hillcrest-challenged pigs. In contrast there was a decrease in both the
mean proportion of lung with lesions and the mean lung score for Beaufort challenged
pigs on day 28 compared to day 21. However, data may have been skewed by the fact
that one of the pigs euthanased 21 days post-challenge had evidence of secondary
bacterial infection, with subacute pneumonia and a GLS of 31. Overall, the highest
prevalence of lesions was found in Hillcrest challenged pigs 28 days pi. No visible
pneumonic lesions were observed in the unchallenged pigs on day 21 or 28.

Table 3.3 Comparison of macroscopic lung lesions in groups challenged with Hillcrest and
Beaufort strains at 21 and 28 days pi (mean ± sem).
Group

21 days
GLS

28 days

% affected

GLS

#

lung

All pigs

% affected

GLS

% affected

lung

lung

Hillcrest

12.75 ± 2.84

6.88 ± 1.40

19.25 ± 12.09

14.90 ± 11.46

16.00 ± 5.88a

10.92 ± 5.56

Beaufort

8.25 ± 7.60

6.45 ± 5.90

3.50 ± 2.25

2.98 ± 2.22

5.88 ± 3.78b

4.72 ± 2.98

GLS: Goodwin lung score;

#

Mean percentage of lung with mycoplasmal-type consolidated lesions (by

weight). Different letter superscripts indicate a significant difference between groups (P<0.05).

3.4.3 Microscopic lesions
M. hyopneumoniae-induced pneumonia, characterised by peribronchiolar and
perivascular lymphoid hyperplasia/cuffing and the accumulation of alveolar exudates
consisting of macrophages, mononuclear and polymorphonuclear leucocytes, was
present in all Hillcrest-infected pigs at day 21 and 28. In contrast, the majority of
Beaufort challenged pigs had normal lung tissue at day 21 and only focal areas of
cuffing of bronchioles and vessels, with an accumulation of macrophages, mononuclear
and polymorphonuclear leucocytes in alveolar spaces at day 28. Occasional lymphoid
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nodules were present in the lungs of control pigs. Additional pathology was evident in
two animals: one of the Hillcrest challenged pigs showed evidence of pleurisy, heart
failure and mild M. hyopneumoniae infection, while one of the Beaufort challenged pigs
had pleurisy and evidence of a subacute bacterial pneumonia (data not shown).

3.4.4 Cytokine responses in TBLF
Cytokine responses in TBLF fluid at 17-18 days pi were more prominent for IL-1β
than for IL-6, and Hillcrest-challenged pigs had significantly higher concentrations of
both cytokines than Beaufort-challenged pigs (P<0.001) (Figure 3.2), reflecting their
greater degree of coughing and lung pathology.

Figure 3.2 Cytokine responses for IL-1β (left) and IL-6 (right) in TBLF of Hillcrest- (black
bars), and Beaufort- (grey bars) challenged pigs before and 17-18 days after challenge,
compared with controls given sterile medium (white bars) (mean ± sem). Within each graph,
different letters above the columns indicate group means are significantly different as
determined by ANOVA (P<0.001).
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3.4.5 Detection and quantification of M. hyopneumoniae in challenged pigs by qPCR
M. hyopneumoniae DNA in right and left lung, spleen, kidney and liver extracts from
Hillcrest- and Beaufort-challenged pigs was detected in the mhp183 qPCR assay. For
tissues, a CT cutpoint of 33 (equivalent to 0.023 ng of M. hyopneumoniae DNA per µL
of tissue extract) was selected on the basis of histopathology results for right and left
lung samples from challenged pigs, and yielded a sensitivity of 97.3% and specificity of
100% (Figure 3.3).

Figure 3.3 Scatter plot of histopathology (HP) scores in right and left lung (0 = normal; 1 =
doubtful; 2, 3, 4 = increasing severity of mycoplasmal type lesions), from pigs inoculated with
Hillcrest (solid squares) or Beaufort strains (open circles), or no organisms (controls; open
triangles) with corresponding CT values obtained by mhp183 qPCR. One sample (not shown)
with HP score 4 gave an undetermined CT value and was classified PCR negative. A CT cutpoint
of 33.0 (horizontal line) was selected on the basis of HP scores where a score of 2, 3 or 4 was
positive for mycoplasmal pneumonia.
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Mycoplasmal DNA was detected by qPCR in the right and left lung of all Hillcrestchallenged pigs at 21 and 28 days pi and in the spleen, kidney and liver of the majority
of Hillcrest-challenged pigs at day 21. Fewer samples from abdominal sites of Hillcrestchallenged pigs were qPCR-positive at 28 days pi. Lung samples from 3 pigs inoculated
with the Beaufort strain were qPCR-positive at 28 days pi. All abdominal tissues
sampled from Beaufort-challenged pigs were qPCR-negative. qPCR did not detect any
mycoplasmal DNA in the left and right lung or abdominal tissues from control pigs
(Table 3.4).

Table 3.4 M. hyopneumoniae DNA concentration (ng/µL of extract) detected by qPCR testing
of lung and abdominal tissue samples from pigs inoculated with Hillcrest or Beaufort strains, or
sterile medium (control), and necropsied at 21 or 28 days pi (mean ± sem).
Group

Hillcrest

Day

21

28

Tissue
RL

LL

S

K

L

128.25 ± 39.28

140.06 ± 49.75

0.11 ± 0.05

0.71 ± 0.64

0.04 ± 0.01

(4/4)

(4/4)
(4/4)

(3/4)

(4/4)

0.11 ± 0.11

0.008 ±

0.005 ±0.005

0.008 (1/4)

(1/4)

0

0

0

0

0

0

51.19 ± 25.67

53.56 ± 20.11

(4/4)

(4/4)
(1/4)

Beaufort

21

85.19 ± 85.19

11.32 ± 7.78

(3/4)
(2/4)
28

11.40 ± 10.80

8.93 ± 4.03

(3/4)
(3/4)
Control

21

0

0

0

0

0

28

0

0

0

0

0

RL: right lung; LL: left lung; S: spleen; K: kidney; L: liver. Brackets indicate the proportion of qPCR
positive animals at a CT cutpoint of 33 (equivalent to 0.023 ng DNA/µL of extracts).
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Overall there were significantly higher (P<0.05) mean concentrations of M.
hyopneumoniae DNA detected in lung samples from challenged pigs compared to
unchallenged pigs, with Hillcrest-challenged pigs having the highest concentration of
mycoplasmal DNA in their lungs. Furthermore, right lung samples had numerically (but
not statistically significant) higher mean concentrations of mycoplasmal DNA than left
lung samples for pigs challenged with either strain. Mean concentrations of
mycoplasmal DNA were significantly higher (P<0.001) in lung than abdominal tissue
samples in pigs challenged with either strain. Within individuals, there was a weak but
significant correlation between the mean mycoplasmal DNA concentration in 15 lung
and liver samples with values above zero (P<0.05, r = 0.52), but not between lung and
kidney or spleen samples.
In Hillcrest-challenged pigs, the mean concentration of mycoplasmal DNA in lung
samples but not the proportion of pigs with positive qPCR results decreased with time.
There was also a general decrease in the mean concentration of DNA in abdominal
tissues of Hillcrest-challenged pigs at day 28 compared to day 21. Whilst the
concentration of M. hyopneumoniae DNA in lung samples from Beaufort-challenged
pigs also decreased with time, the proportion of pigs with positive signals increased on
day 28 compared to day 21 (Table 3.4).
M. hyopneumoniae DNA concentrations in TBLF at day 0 and day 17-18 showed
increases from the pre-challenge concentration in Beaufort and Hillcrest groups, with
numerically higher (but not statistically different, P>0.05) mean concentrations in
Hillcrest-challenged compared with Beaufort-challenged pigs, while control pigs
showed no increase in M. hyopneumoniae DNA concentration (Table 3.5). No
significant differences were detected between CT values of TBLF samples for the two
challenge groups at day 17-18 post-challenge, and there was no significant correlation
between lung lesion severity (lung scores or % affected lung) with CT values or DNA
concentrations in TBLF.
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Table 3.5 M. hyopneumoniae DNA concentrations (ng/µL of extract) in TBLF collected at day
0 (pre-challenge) and at day 17-18 from pigs challenged with Hillcrest or Beaufort strains or
sterile medium (control). Results are the mean ± sem from testing of all samples on two separate
occasions.
Group

Day 0 (all pigs)

Hillcrest
Beaufort

Day 17-18
264.51 ± 230.44

0.46 ± 0.23

Control

57.77 ± 40.26
0.03 ± 0.01

3.5 Discussion and conclusions
The purpose of this study was to compare two field strains of M. hyopneumoniae
(Hillcrest and Beaufort) for their ability to induce mycoplasmal pneumonia, and to
determine the impact of slaughter at 3 or 4 weeks after challenge to confirm disease.
Confirmation of infection by gross and histopathology was also compared with clinical
findings in challenged pigs. Clinical observations revealed coughing was earlier in onset
and more pronounced following Hillcrest challenge than Beaufort challenge. Severity of
pneumonic lesions, as determined by the percentage of affected lung and GLS was also
greater in pigs challenged with the Hillcrest strain. While the Hillcrest strain was
superior to Beaufort in its ability to induce mycoplasmal pneumonia, the outcome of
fixed dose challenge showed considerable variation in the onset of clinical signs and
lung lesion severity. This was not unexpected given that the onset of coughing in
pathogen-free pigs after experimental infection with M. hyopneumoniae is reported to
occur between 7-25 days pi (Sorensen et al. 1997; Irigoyen et al. 1998; Kwon et al.
2002; Vicca et al. 2003; Lorenzo et al. 2006; Villarreal et al. 2011) and will depend on
the virulence of the isolate (Villarreal et al. 2011).
Variation in M. hyopneumoniae strain virulence and the course of clinical disease in
pigs infected with low, moderate or highly virulent isolates is well documented (Vicca
et al. 2003; Meyns et al. 2004, 2007) and may relate to genetic (Frey et al. 1992;
Artiushin and Minon, 1996; Vicca et al. 2003; Stakenborg et al. 2005) and antigenic (Ro
and Ross, 1983) differences among M. hyopneumoniae isolates. Genome sequencing
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and proteomic analysis of pathogenic and non-pathogenic M. hyopneumoniae strains
has provided insight into potential virulence factors (Djordjevic et al. 2004; Minion et
al. 2004; Vasconcelos et al. 2005; Pinto et al. 2009), of which the cilium adhesin (P97)
is the most extensively characterised (Zhang et al. 1995; Hsu et al. 1997; Hsu and
Minion, 1998a, b; Minion et al. 2000). P97 is expressed by the mhp183 gene as a 126
kDa pre-protein which is cleaved at amino acid 195 to produce the functional adhesin
(P97) and an N-terminal fragment (P22). Transposon mutagenesis of P97 and in vitro
microtitre plate adherence assays have identified a proline-rich AAKPV/E repeat region
(R1) located at the carboxy terminus of the mhp183 gene as the cilium- and antibodybinding sites of P97 (Hsu et al. 1997; Hsu and Minion, 1998a), with a minimum of eight
R1 units being required for cilium binding (Minion et al. 2000). Whilst the amino acid
sequence of P97 is highly conserved amongst M. hyopneumoniae strains (Wilton et al.
1998; Jenkins et al. 2006; Stakenborg et al. 2006) the number of tandem 5-amino acid
repeats in R1 varies considerably between isolates with the avirulent strain M.
hyopneumoniae J possessing only nine tandem copies in contrast to the fifteen copies
found in the pathogenic strain 232 (Wilton et al. 1998). The number of tandem repeats
possessed by the Hillcrest strain is unknown; however, as in strain 232 fifteen units are
present in the Beaufort strain (Wilton et al. 1998). It therefore seems unlikely that the
absence of significant clinical disease in the Beaufort-challenged pigs in the present
study is related to the number of adhesin-related R1 repeats in the mhp183 gene.
Adherence by M. hyopneumoniae to epithelial cilia is however, a multifactorial process
involving an array of adhesins, including those which lack R1, (Zhang et al. 1995;
Burnett et al. 2006; Jenkins et al. 2006; Wilton et al. 2009; Deutscher et al. 2010;
Bogema et al. 2011; Seymour et al. 2011) and for which gene expression profiles may
vary amongst pathogenic and non-pathogenic strains (Pinto et al. 2009). Research on
expression of such adhesins in the Hillcrest and Beaufort strains may provide an insight
into adherence capabilities of the isolates and could partially explain the differences in
virulence observed in the present study.
Successive in vitro passage can reduce virulence in mycoplasmas (Whittlestone,
1979; Zielinski and Ross, 1990; DeBey and Ross, 1994). In the present study, passage
levels of the Hillcrest and Beaufort strains were 7 and 15 respectively. It is unclear
whether the higher passage number for the Beaufort strain resulted in decreased
virulence of this isolate. However, M. hyopneumoniae strains 11, 232 and 144L used as
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21st to 27th passage cultures have induced mycoplasmal pneumonia in challenged pigs
(Zielinski and Ross, 1990).
As reported in this study, variation in pneumonic lesion severity can occur in
experimental M. hyopneumoniae challenge systems (Irigoyen et al. 1998; Lorenzo et al.
2006; Villarreal et al. 2009, 2011), even among animals challenged with the same
isolate and dose (Lorenzo et al. 2006) suggesting that the host immune response may
play an important role in the infection pattern and the development of lung lesions
(Messier et al. 1990; Maes et al. 1996). Following adherence to ciliated respiratory
epithelial cells, M. hyopneumoniae induces infiltration of macrophages and
lymphocytes in the perivascular, peribronchial and peribronchiolar areas and alveolar
septa, as well as hyperplasia of lymphoid follicles surrounding the airways (Livingston
et al. 1972; Sarradell et al. 2003). The accumulation of inflammatory cells in the early
stages of infection is considered to represent a response to the presence of inflammatory
cytokines such as IL-1, TNF-α and IL-6 in pneumonic lung (Choi et al. 2006). In our
study, peribronchiolar and perivascular lymphoid hyperplasia/cuffing and the
accumulation of alveolar exudates were more pronounced in Hillcrest-challenged pigs
than in Beaufort-challenged pigs. Analysis of histopathological findings at the two
timepoints revealed that all Hillcrest-challenged pigs had developed typical
mycoplasmal pneumonia by 21 days post-challenge, whereas the majority of Beaufort
challenged pigs developed focal mycoplasmal pneumonia only by 28 days pi. IL-1β and
IL-6 responses in TBLF at 17-18 days pi were significantly elevated in Hillcrestchallenged pigs compared to levels detected in unchallenged pigs. In contrast, there was
a lack of cytokine response in Beaufort-challenged pigs which reflected the absence of
microscopic lesions with this strain at 21 days pi. Together, these results support the
relationship described between cytokine profiles and the occurrence of pneumonic
lesions (Rodriguez et al. 2004; Lorenzo et al. 2006). Overall, IL-1β responses were
more prominent than IL-6, consistent with results of immunohistochemical methods that
showed that IL-1β is more prominent than IL-6 in BALT, alveolar septa and airway
exudates of pigs at 1 to 5 weeks after experimental M. hyopneumoniae challenge
(Lorenzo et al. 2006), and confirms the important role of IL-1β in the early stages of
disease. Higher levels of IL-6 have been detected in BALT of pigs naturally infected
with M. hyopneumoniae when lesions were at a chronic stage (Rodriguez et al. 2004). It
is also known that IL-6 is produced following high levels of IL-1 and TNF-α (Zoja et al.
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1991) and has a negative feedback effect on the production of pro-inflammatory
cytokines (Dinarello, 1992). This suggests a longer experimental challenge system
which monitors cytokine responses at several timepoints may be necessary to establish
the relationship between cytokine concentrations and the stage of disease in porcine
mycoplasmal pneumonia. Earlier experimental studies in specific-pathogen free pigs or
hysterectomy-derived, colostrum-deprived pigs have found elevations of these two
cytokines in lung lavage fluids at 27 and 32 days (IL-1) or at 14, 21 and 28 days (IL-6)
after M. hyopneumoniae infection (Asai et al. 1993, 1994), whereas Choi et al. (2006)
found IL-1 and IL-6 expression peaked in lung at 21 days after infection. Although
using a different method to assess IL-1 and allowing for dilution factors, the
concentration of this cytokine in lung lavage fluid determined by Asai et al. (1994) was
much lower than our findings at 17-18 days. This could be attributed to method
sensitivity, as well as host and M. hyopneumoniae strain differences, or our collection
time coincided with a much higher concentration of IL-1.
Histological findings in the lungs of Hillcrest and Beaufort challenged pigs at 21 and
28 days pi corresponded with the presence and quantity of M. hyopneumoniae DNA
detected by qPCR in lung samples and TBLF from pigs challenged with either isolate.
As suggested by Meyns et al. (2007) it would therefore appear that the observed
differences in virulence is related to a higher capacity to multiply in the lungs and
induce a more severe inflammatory response. The differences in the capacity to multiply
in vivo may be related to the Hillcrest strain having an intrinsically faster growth rate
compared with the Beaufort strain. The capacity to multiply in the lungs may also be
affected by the susceptibility of M. hyopneumoniae isolates to the inhibitory effects of
host immune defences (Meyn et al. 2007).
The lack of statistically significant differences in either mycoplasmal DNA
concentrations in TBLF between challenge groups or in correlations between TBLF
DNA concentrations and lung lesion severity may be due to the small number of
animals used in this study and high variation in DNA concentration between animals
challenged with the same isolate. A previous study with groups of 10 pigs challenged
with M. hyopneumoniae strains of low and high virulence similarly showed high
variation in M. hyopneumoniae DNA in BALF between individuals within a treatment
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and no significant differences between groups of pigs at 4 and 8 weeks following
challenge (Vranckx et al. 2012).
It was also found that the concentrations of mycoplasmal DNA in TBLF were low,
but not absolutely negative in all pigs before challenge and in control pigs at day 17-18.
Since the pigs were derived from a commercial herd considered free of mycoplasmal
pneumonia, it is possible that either TBLF contained low amounts of DNA from
avirulent M. hyopneumoniae strains or from organisms other than M. hyopneumoniae
that cross-react in the qPCR. While the qPCR used is considered highly specific, its
specificity is strongly based on testing cultivable mycoplasmas and other organisms.
Thus non-cultivable organisms in TBLF that contain DNA amplified by the PCR
procedures could have contributed to these results.
The numerically higher concentration of mycoplasmal DNA detected by qPCR in the
right lung compared to the left lung of challenged pigs, which was mainly evident in the
Beaufort-challenged pigs, may be explained by the anatomy of the porcine tracheobronchial tree. The pig trachea branches in a non-symmetrical fashion, with a single
cranial bronchus usually supplying air to the right apical lobe, whereas the left apical
lobe is supplied by a branching of the more caudal stem bronchus that divides to supply
the left apical and cardiac lobes, and continues backward in the diaphragmatic lobe. On
the right side, the stem bronchus supplies the cardiac and accessory (intermediate) lobes
and thence the diaphragmatic lobe (Mouton et al. 1999). Thus from endotracheal
instillation in sternal recumbency, more of the inoculum may be diverted into the right
apical (and cardiac) lobes than the left.
M. hyopneumoniae DNA was detected by qPCR in the spleen, kidney and/or liver of
pigs challenged with the Hillcrest strain. This finding is consistent with previous results
in which M. hyopneumoniae was re-isolated from spleen, kidneys and liver of
experimentally infected pigs (Le Carrou et al. 2006; Marois et al. 2007) and from the
spleen and liver of in-contact pigs (Marois et al. 2007). Previous isolation of M.
hyopneumoniae from lymph nodes of experimentally challenged pigs suggests
dissemination of M. hyopneumoniae to distal tissues may occur by way of the lymphatic
system (Le Carrou et al. 2006). The detection of higher levels of M. hyopneumoniae
DNA by qPCR in abdominal tissues of Hillcrest challenged pigs at 21 compared to 28
days pi supports the theory that whilst there is rapid dissemination of mycoplasma to
Page | 60

these inner organs, colonisation is transitory and thus unlikely to influence the
development of mycoplasmal pneumonia (Le Carrou et al. 2006; Marois et al. 2007).
Considering the weak but significant correlation between mycoplasmal DNA
concentrations in lung and liver, our findings suggest that pigs infected with a more
virulent strain of M. hyopneumoniae are likely to have higher lung concentrations and
these lung concentrations are reflected in liver concentrations. The stronger correlation
between M. hyopneumoniae in lung and liver than with spleen or kidney may be due to
greater dissemination to the liver in heavily infected pigs via lymphatic channels.
Whether transfer from lung lesion sites to the liver can occur or the two concentrations
only reflect an initial dissemination remains unclear, although prior studies where no
organisms were isolated from abdominal organs at 11 weeks (Le Carrou et al. 2006)
suggests limited persistence at these sites.
In conclusion, this study demonstrated that a single dose of the Hillcrest strain, but
not the Beaufort strain, was suitable for inducing clinical signs and gross and
histological lesions indicative of mild to moderate mycoplasmal pneumonia during the
first 3-4 weeks after challenge. Evidence of M. hyopneumoniae infection can be
detected by clinical observation as early as 8 days post-challenge with the Hillcrest
isolate. Furthermore, pathological examination for mycoplasmal-induced lesions can be
conducted at 21 days pi, but lesion severity appears to increase over the next week and
variation in host immune responses may mean that a longer challenge period may be
beneficial for confirmation of disease. The M. hyopneumoniae-specific qPCR assay was
suitable for confirming the presence of mycoplasmal DNA in the lungs of challenged
pigs at 3 or 4 weeks pi and is a reliable method for detecting M. hyopneumoniae in
abdominal tissues.
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4.1 Abstract
Pig responses to recombinant subunit vaccines containing fragments of eight
multifunctional adhesins of the M. hyopneumoniae P97/P102 paralog family formulated
with Alhydrogel® or Montanide™ Gel01 were compared with a commercial bacterin
following experimental challenge. Pigs, vaccinated intramuscularly at 9, 12 and 15
weeks of age with either of the recombinant formulations (n = 10 per group) or
Suvaxyn® M. hyo (n = 12), were challenged with M. hyopneumoniae strain Hillcrest at
17 weeks of age. Unvaccinated, challenged pigs (n = 12) served as a control group.
Coughing was assessed daily. Antigen-specific antibody responses were monitored by
ELISA in serum and TBLF, while TBLF was also assayed for cytokine responses
(ELISA) and bacterial load (qPCR). At slaughter, gross and histopathology of lungs
were quantified and damage to epithelial cilia in the porcine trachea was evaluated by
scanning electron microscopy. Suvaxyn® M. hyo administration induced significant
serological responses against M. hyopneumoniae strain 232 whole cell lysates (wcl) and
recombinant antigen F3P216, but not against the remaining vaccine subunit antigens.
Alhydrogel® and Montanide™ Gel01-adjuvanted antigen induced significant antigenspecific IgG responses, with the latter adjuvant eliciting comparable M. hyopneumoniae
strain 232 wcl specific IgG responses to Suvaxyn® M. hyo. No significant postvaccination antigen-specific mucosal responses were detected with the recombinant
vaccinates. Suvaxyn® M. hyo was superior in reducing clinical signs, lung lesion
severity and bacterial load but the recombinant formulations offered comparable
protection against cilial damage. Lower IL-1β, TNF-α and IL-6 responses after
challenge were associated with reduced lung lesion severity in Suvaxyn® M. hyo
vaccinates, while elevated pathology scores in recombinant vaccinates corresponded to
cytokine levels that were similarly elevated as in unvaccinated pigs. This study
highlights the need for continued research into protective antigens and vaccination
strategies that will prevent M. hyopneumoniae colonisation and establishment of
infection.
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4.2 Introduction
M. hyopneumoniae, the causative agent of mycoplasmal pneumonia, is a common and
economically significant pathogen of swine (Thacker et al. 2006). Commercial bacterinbased vaccines can reduce clinical signs of mycoplasmal pneumonia, but do not prevent
transmission or establishment of M. hyopneumoniae in the lungs (Thacker et al. 2000).
For infection to occur, M. hyopneumoniae must adhere to ciliated respiratory
epithelium. Extensive characterisation of the surface-accessible M. hyopneumoniae
P97/P102 paralog family members has found them to be multifunctional cilium
adhesins which exploit host surface glycoconjugates and extracellular matrix
components to facilitate M. hyopneumoniae pathogenesis (Zhang et al. 1995; Burnett et
al. 2006; Jenkins et al. 2006; Wilton et al. 2006; Deutscher et al. 2010, 2012; Bogema et
al. 2011, 2012; Seymour et al. 2010, 2011, 2012). Despite the broad range of host
molecule interactions displayed by the P97/P102 paralog family of proteins, only P97
has been investigated as a potential vaccine candidate (King et al. 1997; Chen et al.
2001; Conceicao et al. 2006). Following colonisation of cilia, M. hyopneumoniae
induces the secretion of numerous cytokines including IL-1β, IL-6 and TNF-α
(Rodriguez et al. 2004; Choi et al. 2006; Lorenzo et al. 2006; Woolley et al. 2012, 2013;
Chapters 3 and 5). Detection of elevated levels of IL-1β, IL-6 and TNF-α in the
pneumonic lungs of swine during the early stages of infection suggests these cytokines
are key mediators of the chronic inflammatory response that is the hallmark of
mycoplasmal pneumonia (Rodriguez et al. 2004; Choi et al. 2006; Lorenzo et al. 2006;
Woolley et al. 2012, 2013; Chapters 3 and 5). The mechanisms by which M.
hyopneumoniae induces immunopathologic modifications remain poorly understood;
however, protection against mycoplasmal infection in swine is purported to be afforded
by both cell-mediated and humoral immunity (Thacker et al. 2000). Aluminiumcontaining adjuvants, of which Alhydrogel® is an example, are widely used
immunopotentiators (Naim et al. 1997) which predominantly induce humoral immunity
by providing Th2 cell assistance to follicular B cells (Brewer et al. 1999). A major
drawback of aluminium adjuvants is their inability to stimulate cell-mediated Th1 or
cytotoxic T-lymphocyte responses (Edelman, 2002). In contrast, Montanide™ Gel01 is
a stable, well tolerated, polymer based adjuvant that has been documented to induce
humoral and/or cellular immune responses in pigs following intramuscular
administration of the adjuvant emulsion containing Bordetella bronchiseptica cell wall
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components and anatoxins of Pasturella multocida (Seppic Technical Bulletin, 2008),
and therefore represents a promising adjuvant for inducing a protective immune
response against infection of swine by M. hyopneumoniae. In this study, recombinant
P102 (rP102) (Seymour et al. 2012) as well as recombinant fragments representing
functional domains within several of the P97/P102 paralogs, including F2P97 (Jenkins et
al. 2006), F3P216 (Wilton et al. 2006), F4P159 (Burnett et al. 2006), F3P135, F4P135
(Bogema et al. 2011), F1P146 (Bogema et al. 2012) and F3P116 (Seymour et al. 2010)
were trialled as a subunit vaccine cocktail for protection against M. hyopneumoniae
infection. The recombinant antigens, formulated with Alhydrogel® or Montanide™
Gel01, were administered intramuscularly to pigs and their immunogenicity was
assessed via ELISAs monitoring antigen-specific IgG and IgA responses in serum and
TBLF respectively. The ability of each formulation to prevent M. hyopneumoniae
colonisation and various clinical disease parameters following experimental infection
was compared to that of the commercial bacterin Suvaxyn® M. hyo (Virbac, Australia).

4.3 Materials and methods
4.3.1 Bacterial challenge and antigen strain culture
The M. hyopneumoniae strain Hillcrest is an Australian field isolate (Seymour et al.
2011), and was selected for use in the present study on the basis of strain pathogenicity
as evidenced in our previous experimental challenge system (Woolley et al. 2012;
Chapter 3). The Hillcrest strain was cultivated in modified Friis medium as previously
described (Scarman et al. 1997). E. coli strains were grown at 37˚C in LB broth at 250
rpm or on LB agar (Sambrook et al. 1989) supplemented with ampicillin at 100 µg/mL
and kanamycin at 50 µg/mL.

4.3.2 Cloning, expression and purification of recombinant 6×His- and GST-tagged
protein
The cocktail subunit vaccines were formulated with 6×His-tagged proteins. To rule
out the possibility that the 6×His tag on each vaccine antigen generated cross-reactive
antibodies in pigs vaccinated with the subunit cocktail, antigen-specific immune
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responses were monitored via ELISA with the corresponding GST-tagged proteins. The
6×His-tagged proteins were purified under denaturing conditions by nickel affinity
chromatography on Profinity™ IMAC resin (Bio-Rad, USA) from IPTG-induced pET
expression vectors containing previously cloned M. hyopneumoniae gene fragments
coding for F2P97, rP102, F3P216, F4P159, F3P135, F4P135, F1P146 and F3P116 (Burnett et al.
2006; Jenkins et al. 2006; Wilton et al. 2006; Seymour et al. 2010, 2012; Bogema et al.
2011, 2012) as previously described (Jenkins et al. 2006). Equivalent M.
hyopneumoniaep p97/p102 paralog family gene fragments (amplified using the primers
listed in Table 5.1) were cloned into the pGEX-2T vector (GE Healthcare, USA) and
expressed GST-tagged proteins were purified under native conditions on a glutathioneagarose column as previously described (Deutscher et al. 2010).

Table 4.1 Primers used in this study for cloning mhp genes coding for F2P97, rP102, F3P216,
F4P159, F3P135, F4P135 and F3P116 into pGEX-2T.
Target

Primer sequence (5’-3’)a

F2P97

F: ggggatccaaattagacgataatcttcag
R: gggaattcttaggatcaccggattttgaa

rP102

F: gggatccgcagaagaagctaagggtcaa
R: gggaattcttctaaagtaaagaaatttgg

F3P216

F: gggatccgaagaaatagctgagctagat
R: gggaattcgaacgatcaattggtgttccc

F4P159

F: ggggatccacaaaataacaactttccaa
R: gggaattcagaataattcttaaaatattg

F3P135

F: ggggatccgattggataactttagggaga
R: gggaattcatcccaggtagttcctggtag

F4P135

F: ggggatccacctgggatttccatgttgaa
R: ggggattccagtccagagaacttcaccttg

F3P116

F: ggggatccggtgattttactatcgaattt
R: gggaattctagccctgaatcaagccgtga

a

Restriction sites for BamHI in the forward (F) primers and EcoRI in the reverse (R) primers are

underlined.
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4.3.3 Preparation of recombinant 6×His-tagged protein-Alhydrogel® and Montanide™ Gel01 vaccine cocktails
Alhydrogel® (Accurate Chemical and Scientific Corporation, USA) or Montanide™
Gel01 (Seppic, France) was added to a 600 µg/mL cocktail of the 6×His-tagged
antigens (75 µg/mL of each protein), at a ratio of 1:2 (v/v) and 1:4 (v/v) respectively.
Antigen-adjuvant solutions were vortexed and mixed on a roller at room temperature for
30 min.

4.3.4 Vaccination, challenge, clinical evaluation and collection of TBLF and sera
All animal procedures were approved by the Animal Ethics Committee at the
Elizabeth Macarthur Agricultural Institute and were in accordance with the Australian
Code of Practice for the Care and Use of Animals for Scientific Purposes. Forty-four
male weaner pigs (Large White × Landrace, 8 weeks old) obtained from a high health
status herd (considered M. hyopneumoniae-free on the basis of long term history of
slaughter examination and clinical history) were assigned to one of the following
treatment groups; Alhydrogel® (A, n = 10), Montanide™ Gel01 (M, n = 10), Suvaxyn®
M. hyo (S, n = 12) or unvaccinated (U, n = 12). Pigs were housed in groups of five-tosix in four rooms (separated into two airspaces, with a duplication of the four treatment
groups per airspace) in a temperature controlled (22-25˚C) experimental piggery and
had ad libitum access to a commercial pelleted diet (13.7 MJ digestible energy/kg) free
from antibiotics. At 9 weeks of age pigs were administered intramuscularly with 2 mL
of either the recombinant protein cocktail Alhydrogel® or Montanide™ Gel01
formulations or Suvaxyn® M. hyo vaccine (Virbac, Australia). Pigs were vaccinated for
the first time at 9 weeks of age to avoid the risk of interference from maternal immunity
(Hodgins and Dewey, 2004), and potentially confounding issues of concurrent E. coli
infections which may impair an ideal immune response to vaccination. Vaccinations
were repeated when pigs were 12 and 15 weeks old. Pigs in the unvaccinated group did
not receive any treatment. Two weeks following the final dose of vaccine, all pigs were
anaesthetised and inoculated endotracheally with 10 mL of M. hyopneumoniae strain
Hillcrest culture containing 1-2 × 1013 colour change units (CCU) per mL (Freundt and
Erno, 1979; Woolley et al. 2013; Chapter 5, Section 5.3.2). Pigs were monitored daily
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throughout the trial and cumulative coughing scores were calculated (Woolley et al.
2012; Chapter 3, Section 3.3.4). Serum was collected from all pigs prior to vaccination,
post-vaccination (i.e. post final immunisation but pre-challenge) and at slaughter. TBLF
was collected from all pigs prior to challenge and at 3 and 5 wpi (Woolley et al. 2013;
Chapter 5, Section 5.3.2). All pigs were euthanased at 6 wpi.

4.3.5 Evaluation of antigen-specific immune responses and cytokine responses in
serum and/or TBLF
Antigen-specific serum IgG and TBLF IgA levels from vaccinated and unvaccinated
challenged pigs were monitored by ELISA as previously described (Eamens et al. 2008)
but with the following modifications. The wells of the microtitre plates were separately
coated with the recombinant proteins (5 µg/mL) or M. hyopneumoniae strain 232 whole
cell lysates (wcl) (2.5 µg/mL) in carbonate buffer (pH 9.6) overnight. Serum and TBLF
were diluted 1:400 and 1:8 respectively in 1% skim milk in PBS, and plates were
incubated at room temperature. Bound antibodies were detected with HRP-conjugated
goat anti-swine IgG (KPL, USA) or goat-anti swine IgA (Bethyl Laboratories Inc.,
USA) diluted 1:10,000 in 1% skim milk in PBS. The optical density at 414 nm was
measured when the ratio of mean positive to negative control sera or TBLF was within
the range of 3 to 5. Results were expressed as an adjusted ELISA ratio (ER) (Eamens et
al. 2008).
Purification of the GST-F1P146 protein was prevented by steric inhibition of the GSTglutathione interaction; therefore, cross-reactivity of the pig sera with the 6×His-tag on
F1P146 was ruled out via a blocking ELISA with mouse anti-pentaHis antibodies
(Qiagen, Australia). This ELISA was performed as described above but with the
addition of a 1 h incubation step with mouse anti-PentaHis antibodies diluted in 1%
BSA in PBS to 0.19 ng/µL, a concentration shown to detect the His-tag on F1P146.
Bound antibodies were detected following a 1 h incubation with HRP-conjugated sheep
anti-mouse IgG (Chemicon Australia, Australia) diluted 1:10,00 in 1% skim milk in
PBS.
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IL-1β, TNF-α and IL-6 levels in TBLF were monitored using Porcine Quantikine®
ELISA kits (R&D Bio-Scientific Pty Ltd, Australia) as previously described (Woolley
et al. 2012; Chapter 3, Section 3.3.6).

4.3.6 Tissue sample collection and pathologic examination
At necropsy, gross and histopathology of lungs were quantified as previously
described (Goodwin et al. 1969; Woolley et al. 2013; Chapter 5, Section 5.3.4). A 2 cm2
full-thickness section of tissue was collected from the tracheal bifurcation of each pig,
fixed in 2.5% glutaraldehyde for 2 days at 4˚C and stored in PBS at 4˚C until scanning
electron microscopy (SEM).

4.3.7 Determination of bacterial load in TBLF
The concentration of M. hyopneumoniae DNA in TBLF was determined using the
previously described mhp183 qPCR assay (Strait et al. 2008) with minor modifications
(Woolley et al. 2012; Chapter 3, Section 3.3.7). In contrast to our previous study
(Woolley et al. 2012; Chapter 3), the qPCR assay was only performed on TBLF, as
BAL and tracheobronchial sites are the most predictive of infection (Kurth et al. 2002).

4.3.8 Scanning electron microscopic observation of tracheal samples
Fixed tracheal samples were washed in cacodylate buffer (0.1 M sodium cacodylate,
0.01 M CaCl2, 0.01 M MgCl2 and 0.09 M sucrose, pH 6.9) and post-fixed in 1%
osmium tetroxide (ProSciTech, Australia) in cacodylate buffer for 72 h at 4˚C. After
further washing with cacodylate buffer, samples were dehydrated in an ethanol series. A
1:1 solution of hexamethyldisilazane (HMDS) (Sigma-Aldrich) and 100% ethanol was
added for 5 min followed by two exchanges with 100% HMDS, allowing the final
exchange to evaporate completely for at least 24 h. Carbon was then vacuum deposited
using a MED 010 Balzers Union Carbon Coater onto the samples to give a 10 nm
coating. Samples were imaged on a Zeiss Supra 55VP using the in-lens detector to
collect secondary electrons at 2-5 kV.
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4.3.9 Statistical analyses
Univariate analyses were used to compare coughing episodes, severity of pneumonic
lesions, bacterial load, cytokine responses and systemic and mucosal immune responses
between treatment groups. Each analysis respected the trial design: mixed models were
used with fixed effects of treatment group, and random effects of airspace and group
within airspace. Prior to data analysis, a square root transformation of coughing scores
and a natural logarithm (Ln) transformation for each lung score variable as well as
bacterial load, cytokine and humoral responses were used to reduce variance
heterogeneity. For variables taking zero values, a Ln(x+c) transformation was applied
where c was a small constant (half the minimum non-zero value). Variables measured at
more than one time point were also analysed using a bivariate analysis to assess whether
there were significant changes in mean responses for a given treatment group overtime,
and whether mean differences between treatment groups varied significantly throughout
the trial. Each bivariate analysis included the fixed effects of treatment group, week and
treatment group by week interactions, and random effects of airspace and group within
airspace as well as each of their interactions with week. Results were considered
significantly different at P-values < 0.05, unless noted otherwise. Back-transformed
means are presented, corresponding to geometric means on the original scale.

4.4 Results
4.4.1 Serum antibody responses
Pigs showed no significant mean antigen-specific serum IgG responses in any
treatment group prior to vaccination (P>0.05). Post-vaccination (but prior to challenge),
Alhydrogel® and Montanide™ Gel01 vaccinates had significantly elevated mean
antigen-specific serological responses compared with Suvaxyn® M. hyo and
unvaccinated pigs (Figure 4.1, A-I) (P-values presented in Table 4.2). Furthermore, the
Montanide™ Gel01 formulation stimulated mean M. hyopneumoniae strain 232 wclspecific serum IgG responses comparable to that induced by immunisation with the
commercial bacterin (Figure 4.1, I) (P>0.05). In regards to Suvaxyn® M. hyo
administration, a significant increase in mean serum IgG antibodies was detected after
vaccination compared with pre-vaccination levels for M. hyopneumoniae strain 232 wcl
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(Figure 4.1, I) and F3P216 (Figure 4.1, C) (P<0.001) but not for any of the remaining
subunit antigens (P>0.05). At slaughter (6 wpi), mean antigen-specific serum IgG
responses had generally increased in Alhydrogel®, Suvaxyn® M. hyo and unvaccinated
pigs compared with post-vaccination levels (Figure 4.1, A-I) (P-values presented in
Table 4.2). At necropsy the highest mean antigen-specific serum IgG levels were
typically detected in Montanide™ Gel01 vaccinates; though in comparison to postvaccination levels, serological responses had begun to subside in Montanide™ Gel01
vaccinated pigs for all antigens except rP102 (Figure 4.1, B) (P<0.001), F1P146 (Figure
4.1, G) (P>0.05) and M. hyopneumoniae strain 232 wcl (Figure 4.1, I) (P>0.05).
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Figure 4.1 ELISA ratios (geometric mean on original scale ± sem) for antigen specific serum
IgG antibody responses in vaccinated and unvaccinated pigs subsequently challenged with M.
hyopneumoniae strain Hillcrest. Antibody responses against F2P97 (A), rP102 (B), F3P216 (C),
F4P159 (D), F3P135 (E), F4P135 (F), F1P146 (G), F3P116 (H) and M. hyopneumoniae strain 232 whole
cell lysate (wcl) (I) are shown as white (Alhydrogel®), grey (Montanide™), striped (Suvaxyn®
M.hyo) or black (unvaccinated) bars. Serum samples were collected prior to vaccination (PreVac), post-vaccination/pre-challenge (Post-Vac) and at slaughter 6 weeks post-challenge.
Statistical results for bivariate analyses between treatment groups at each time point and for
week and treatment group interactions are described in text and presented in Table 4.2.
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Table 4.2 Bivariate analysis of serum IgG antibody responses against individual antigens in
vaccinated pigs subsequently challenged with M. hyopneumoniae strain Hillcrest.
Antigen

P-values (LSR)a for effects of treatment group

P-values (LSR)a for

at:

effects of time:

Pre-

Post-vaccination

Slaughter

vaccination

a

F2P97

>0.05

<0.001 (1.415)

<0.001 (1.677)

>0.05

rP102

>0.05

<0.01 (1.740)

<0.01 (1.498)

<0.001 (1.471)

F3P216

>0.05

<0.001 (1.395)

<0.001 (1.652)

<0.001 (1.381)

F4P159

>0.05

<0.001 (1.467)

<0.01 (1.478)

>0.05

F3P135

>0.05

<0.001 (1.391)

<0.001 (1.656)

>0.05

F4P135

>0.05

<0.001 (1.372)

<0.05 (1.459)

<0.001 (1.401)

F1P146

>0.05

<0.001 (1.425)

<0.001 (1.412)

<0.05 (1.162)

F3P116

>0.05

<0.01 (1.618)

>0.05

>0.05

232 wcl

>0.05

<0.001 (1.247)

<0.01 (1.318)

<0.001 (1.210)

Least significant ratio (LSR) values indicate the smallest significant ratio between two means. No LSR

value is given where P>0.05.

4.4.2 TBLF antibody responses
There was no significant elevation in mean antigen-specific mucosal immune
responses following vaccination (but prior to challenge) in any of the treatment groups
compared with unvaccinated pigs except for M. hyopneumoniae strain 232 wcl (Figure
4.2, I) in Suvaxyn® M. hyo vaccinates (P<0.05). However, mean post-vaccination IgA
TBLF responses were numerically but not significantly higher for several antigens in
Alhydrogel® (F4P135, F3P116, M. hyopneumoniae strain 232 wcl, Figure 4.2, F, H and I,
respectively) and Suvaxyn® M. hyo (rP102, F4P159, F3P135, F4P135, Figure4.2, B, D, E
and F, respectively) pigs compared with unvaccinated pigs (P>0.05). Three wpi mean
IgA TBLF responses had generally increased in all treatment groups compared with
post-vaccination (pre-challenge) levels. Significantly higher mean IgA responses
against rP102 (Figure 4.2, B) were detected in all vaccinated treatment groups compared
with unvaccinated pigs at this time point (P<0.001). By 5 wpi, mean mucosal responses
had begun to subside for Suvaxyn® M. hyo pigs. Similarly, antigen-specific IgA levels
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were typically lower at 5 wpi compared to 3 wpi for Alhydrogel® vaccinates. In
contrast, mean mucosal responses against several of the antigens had increased in
Montanide™ Gel01 pigs relative to levels detected earlier in the trial; however, only
mean anti-rP102 and F4P159 serum IgG responses were significantly elevated compared
with unvaccinated challenged pigs at the same time point (Figure 4.2, B and D
respectively) (P<0.001 and P<0.05 respectively) (P-values presented in Table 4.3).
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Figure 4.2 ELISA ratios (geometric mean on original scale ± sem) for antigen specific TBLF
IgA antibody responses in vaccinated and unvaccinated pigs subsequently challenged with M.
hyopneumoniae strain Hillcrest. Antibody responses against F2P97 (A), rP102 (B), F3P216 (C),
F4P159 (D), F3P135 (E), F4P135 (F), F1P146 (G), F3P116 (H) and M. hyopneumoniae strain 232 whole
cell lysate (wcl) (I) are shown as white (Alhydrogel®), grey (Montanide™), striped (Suvaxyn®
M.hyo) or black (unvaccinated) bars. TBLF samples were collected post-vaccination/prechallenge (Post-Vac) and at 3 wpi and 5 wpi. Statistical results for bivariate analyses between
treatment groups at each time point and for week and treatment group interactions are described
in text and presented in Table 4.3.
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Table 4.3 Bivariate analysis of TBLF IgA antibody responses against individual antigens in
vaccinated pigs subsequently challenged with M. hyopneumoniae strain Hillcrest.
Antigen

P-values (LSR)a for effects of treatment group at:

P-values (LSR)a for
effects of time:

a

Post-Vaccination

3 weeks PI

5 weeks PI

F2P97

<0.05 (1.380)

>0.05

>0.05

<0.001 (1.811)

rP102

>0.05

<0.001 (1.751)

<0.001 (1.813)

>0.05

F3P216

>0.05

>0.05

>0.05

>0.05

F4P159

>0.05

>0.05

<0.05

>0.05

F3P135

>0.05

>0.05

>0.05

>0.05

F4P135

>0.05

>0.05

>0.05

<0.001 (1.464)

F1P146

>0.05

>0.05

>0.05

>0.05

F3P116

>0.05

>0.05

>0.05

<0.001 (1.478)

232 wcl

<0.05 (1.174)

<0.001 (1.439)

<0.01 (1.415)

<0.001 (1.301)

Least significant ratio (LSR) values indicate the smallest significant ratio between two means. No LSR

value is given where P>0.05.

4.4.3 Clinical disease and lung pathology
Dry, non-productive coughing indicative of mycoplasmal pneumonia was observed in
all treatment groups from as early as 8 to 10 days pi and continued throughout the trial.
Coughing severity was numerically lower in Alhydrogel® and Montanide™ Gel01
vaccinates compared with unvaccinated pigs (P>0.05); however, only Suvaxyn® M. hyo
administration significantly reduced mean coughing severity (P<0.05) (Table 4.4).
Lung lesions indicative of mycoplasmal pneumonia were observed in all treatment
groups and were characterised by an accumulation of lymphocytes, macrophages and
neutrophils in the perivascular, peribronchial and peribronchiolar areas and alveolar
septa. Although high variability in lung lesion severity in pigs within each group made
it difficult to detect any significant differences among treatment groups (P>0.05),
pneumonic lesions were consistently less prominent for Suvaxyn® M. hyo pigs
(P>0.05). Interestingly, mean lung score variables were typically higher, though not
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significantly so, in Alhydrogel® and Montanide™ Gel01 vaccinates compared with
unvaccinated pigs (P>0.05) (Table 4.4).

Table 4.4 Comparison of clinical coughing scores, macroscopic lung lesions and lung
pathology score between vaccinated (Alhydrogel®, A; Montanide™ Gel01, M; Suvaxyn® M.
hyo, S) and unvaccinated (U) pigs challenged experimentally with M. hyopneumoniae strain
Hillcrest (geometric mean on original scale ± sem).
Treatment

Coughing score

% affected lung

GLS

scorea

weight

a

Pathology

A

0.15 ± 0.02

0.83 ± 1.67

2.37 ± 1.29

4.08 ± 1.77

M

0.11 ± 0.02

0.80 ± 1.22

2.01 ± 1.15

3.49 ± 1.39

S

0.03 ± 0.03b

0.05 ± 1.75

0.35 ± 1.17

0.25 ± 1.51

U

0.20 ± 0.03

0.34 ± 1.87

1.41 ± 1.26

2.03 ± 1.71

Pathology score represents the result of Goodwin lung score (GLS) at slaughter multiplied by

histopathology severity score.

b

Significant difference for mean coughing scores between treatment

groups (P<0.05).

4.4.4 Bacterial load in TBLF and cilial damage
Pre-challenge levels of mycoplasmal DNA in TBLF was negligible and did not vary
significantly between treatment groups (P>0.05). Following challenge, there was a
significant increase in mean bacterial load in TBLF for all treatment groups (P<0.001).
At 3 wpi Suvaxyn® M. hyo vaccinates had a significantly reduced mean bacterial load
compared with unvaccinated pigs (P<0.05). Of the recombinant vaccinates only
Montanide™ Gel01 pigs had numerically (although not significantly) lower levels of
mycoplasmal DNA in their TBLF than unvaccinated pigs at this time point (P>0.05).
Mean bacterial load in TBLF had declined within all treatment groups at 5 wpi
compared to 3 wpi, with significant reductions for Suvaxyn® M. hyo vaccinates
(P<0.001). However in comparison to unvaccinated pigs, only Suvaxyn® M. hyo
vaccinates had significantly lower mean levels of mycoplasmal DNA in the upper
respiratory tract at 5 wpi (P<0.001) (Figure 4.3).
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Figure 4.3 Bacterial load (geometric mean on original scale ± sem), measured as the
concentration of M. hyopneumoniae (Mhp) DNA in TBLF from vaccinated (Alhydrogel®, white
bars; Montanide™, grey bars; Suvaxyn® M.hyo, striped bars) and unvaccinated (black bars)
pigs at 3 wpi and 5 wpi with M. hyopneumoniae strain Hillcrest. The mean concentration of M.
hyopneumoniae DNA in TBLF from Suvaxyn® M. hyo vaccinates declined significantly at 5
wpi compared to 3 wpi (a, b; P<0.001). Bacterial load was also significantly lower in Suvaxyn®
M. hyo pigs at 3 wpi (P<0.05) and 5 wpi (P<0.001) compared to the other treatment groups at
the same timepoints (*). Pre-challenge levels of M. hyopneumoniae DNA were not absolutely
negative in all pigs (range 0-0.05 ng/µL); however, mean bacterial load in TBLF was below the
assigned CT cutpoint of 33 and therefore not displayed on the graph.
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SEM of tracheal samples from unvaccinated pigs revealed many areas of epithelial
cells devoid of cilia or having clumped cilia that had lost parallel arrangement and
gentle curvature. In vaccinated, challenged pigs, epithelial cells were mostly ciliated and
cilia typically appeared to be similar in length and diameter (Figure 4.4).

A

2µm

C

2µm

B

2µm

D

2µm

Figure 4.4 Scanning electron micrographs from sections of fixed tracheal samples (collected
from the tracheal bifurcation) at a magnitude of 4,000× and 15,000× (insert) from Alhydrogel®
(A), Montanide™ Gel01 (B) and Suvaxyn® M.hyo (C) vaccinated pigs and unvaccinated pigs
(D) at 6 weeks after experimental infection with M. hyopneumoniae strain Hillcrest. Imaged at 5
kV except for the control (D), which was imaged at 2 kV. Bar = 2µm.
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4.4.5 Cytokine responses in TBLF
Post-vaccination (but prior to challenge) the mean levels of IL-1β, TNF-α and IL-6 in
TBLF from vaccinated pigs did not vary significantly from each other or when
compared with unvaccinated control animals (P>0.05) (Figure 4.5). As expected, mean
levels of all pro-inflammatory cytokines increased following challenge, and were
typically higher at 3 wpi compared with 5 wpi for all treatment groups. After challenge,
mean IL-1β, TNF-α and IL-6 responses for the two recombinant vaccine groups did not
vary significantly from each other or when compared with unvaccinated pigs at any
given time point (P>0.05). In contrast, Suvaxyn® M. hyo pigs had significantly lower
mean IL-1β responses at both 3 wpi (P<0.001) and 5 wpi (P<0.001), TNF-α responses
at 3 wpi (P<0.05) and 5 wpi (P<0.01), and IL-6 responses at 3 wpi (P<0.01) compared
with all treatment groups (Figure 4.5) (P-values presented in Table 4.5).
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Figure 4.5 Cytokine responses for IL-β (A), TNF-α (B) and IL-6 (C) in TBLF from vaccinated
(Alhydrogel®, white bars; Montanide™, grey bars; Suvaxyn® M.hyo, striped bars) and
unvaccinated (black bars) pigs post-vaccination/pre-challenge (Post-Vac) and at 3 wpi and 5
wpi with M. hyopneumoniae strain Hillcrest (geometric mean on original scale ± sem).
Following challenge, mean pro-inflammatory cytokine levels in TBLF were, with the exception
of IL-6 responses at 5 wpi, significantly lower in Suvaxyn® M. hyo vaccinates compared with
all treatment groups at the same time point. These statistical results are indicated on the graph as
follows; *, P<0.05; **, P<0.01; ***, P<0.001. Statistical results for bivariate analyses of week
and treatment group interactions are presented in Table 4.5.
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Table 4.5 Bivariate analysis of cytokine responses for IL-1β, TNF-α and IL-6 in TBLF from
vaccinated and unvaccinated pigs post-vaccination/pre-challenge and at 3 wpi and 5 wpi with
M. hyopneumoniae strain Hillcrest.
Cytokine

P-values (LSR)a for effects of treatment group at:

P-values (LSR)a for
effects of time:

Post-

3 weeks PI

5 weeks PI

Vaccination

a

IL-1β

>0.05

<0.001 (3.165)

<0.001 (7.941)

<0.001 (5.392)

TNF-α

>0.05

<0.05 (7.838)

<0.01 (5.312)

>0.05

IL-6

-

<0.01 (6.038)

>0.05

<0.001 (5.186)

Least significant ratio (LSR) values indicate the smallest significant ratio between two means. No LSR

value is given where P>0.05.

4. 5 Discussion and conclusions
Administration of M. hyopneumoniae bacterins is known to induce specific antibody
secretions in serum (Marchioro et al. 2013) and the respiratory tract of swine (Thacker
et al. 2000). Our results were consistent with these reports, with Suvaxyn® M. hyo
immunisation stimulating significant mean humoral responses to M. hyopneumoniae
strain 232 wcl in serum and TBLF, an effect boosted by challenge. Interestingly, none
of the recombinant fragments utilised in the cocktail vaccines were significantly
recognised by antibodies following Suvaxyn® M. hyo vaccination, except for F3P216,
which was recognised by serum antibodies. This was unexpected given that these
cleavage fragments interact with porcine cilia as well as host glycoconjugates and
extracellular matrix components and are thus likely to be essential factors of the M.
hyopneumoniae virulence repertoire (Burnett et al. 2006; Jenkins et al. 2006; Wilton et
al. 2006; Seymour et al. 2010, 2012; Bogema et al. 2011, 2012). Certainly, P97 is an
immunodominant antigen capable of inducing specific antibody responses in M.
hyopneumoniae infected swine (Young et al. 1990) and has been shown, along with
F3P216, F3P135 and F4P135, to be recognised by convalescent-phase pig sera (Djordjevic et
al. 2004; Wilton et al. 2006; Bogema et al. 2011). Perhaps Suvaxyn® M. hyo
administration failed to elicit post-vaccination antibodies to the recombinant fragments
as a result of mutations in putative virulence factor coding sequences including those of
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P97, P102, P216, P159 and P146 (Lui et al. 2013) which may have arisen during in
vitro maintenance of the bacterin culture (Calus et al. 2007). Indeed, the proteomic
expression profile of the extensively passaged non-pathogenic strain J, on which
commercial bacterins are typically based, was previously shown to clearly deviate from
several field isolates (Calus et al. 2007). In the current study, subsequent challenge of
Suvaxyn® M. hyo vaccinates did, however, improve detection of the recombinant
antigens in serum and TBLF, suggesting that the fragments are potentially
immunogenic, at least in a live infectious strain.
As expected, intramuscularly-administered Alhydrogel® and Montanide™ Gel01
vaccines resulted in enhanced mean antigen-specific serum IgG antibody levels, with
the latter being the superior adjuvant. Of particular importance, while mean postvaccination M. hyopneumoniae-specific serum IgG responses were numerically elevated
in Montanide™ Gel01 vaccinates compared with Suvaxyn® M. hyo vaccinated pigs, the
commercial bacterin was more effective in reducing clinical symptoms and lung lesions
associated with mycoplasmal pneumonia. As in previous studies, such results raise the
issue of whether serum antibody responses to M. hyopneumoniae are protective
(Djordjevic et al. 1997; Thacker et al. 1998, 2000). To date, no reliable direct
correlation has been found between the induction of systemic humoral responses and
protection against M. hyopneumoniae infection (Djordjevic et al. 1997; Thacker et al.
1998). On the other hand, administration of partially protective commercial bacterins
has, as in the present study, been shown to correlate with elevated levels of mucosal
antibodies (Young et al. 1990; Thacker et al. 2000). Since M. hyopneumoniae colonises
the respiratory tract of swine, it is logical that antibodies in this compartment are likely
to be important for protection against mycoplasmal pneumonia (Thacker et al. 1998).
Furthermore, the absence of such a response in Alhydrogel® and Montanide™ Gel01
vaccinated pigs may in part explain why the recombinant formulations did not offer
complete protection against clinical disease. Together these results warrant continued
optimisation of vaccine delivery through a combination of a more appropriate
immunisation route and selection of an appropriate mucosal adjuvant. Immunisation
regimes which combine the use of primary exposure to antigens by the systemic route
with direct presentation to the respiratory mucosa may also be beneficial for inducing
prolonged and persistent humoral responses. This approach has been proposed to lead to
the homing of effector lymphocytes generated after primary exposure to an antigen to a
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final location that is determined by secondary exposure to the antigen (Davenport et al.
2000), and proved successful in the development of protective anti-M. pneumoniae
antibodies in guinea pigs (Hausner et al. 2013) and improved the efficacy of a
Chlamydia trachomatis recombinant vaccine (Ralli-Jain et al. 2010) as well as an
equine influenza ISCOM vaccine (Crouch et al. 2005).
Of the P97/P102 paralog family members, only P97 has previously been investigated
as a potential vaccine candidate. Prior studies in pigs immunised with recombinant P97
formulated as a subunit vaccine (King et al. 1997), fused to mucosal adjuvants
(Conceicao et al. 2006) or associated with attenuated bacterial or viral vectors (Ogawa
et al. 2009; Okamba et al. 2010) have shown reduced severity of mycoplasmal
pneumonia, and support the involvement of P97 in the initial establishment of infection
(King et al. 1997). Interestingly, our results indicated that mean bacterial load in TBLF
from the recombinant vaccinates was numerically elevated compared with unvaccinated
pigs at 3 wpi and/or 5 wpi. However, given the healthy appearance of epithelial cilia in
the respiratory tract of Alhydrogel® and Montanide™ Gel01 vaccinated pigs, these
results may have been skewed by detection of non-viable bacterial cells that had been
cleared into the mucus of the recombinant vaccinates (Marois et al. 2010).
Mycoplasmal pneumonia-induced lung inflammation has previously been shown to
correlate with elevated levels of pro-inflammatory cytokines in bronchus-associated
lymphoid tissue, alveolar septa and/or airway exudates of pigs following experimental
challenge (Choi et al. 2006; Lorenzo et al. 2006) or natural infection (Rodriguez et al.
2004). Indeed, a reduction in lung tissue damage following experimental challenge of
pigs immunised with a commercial bacterin has been suggested to be due to a
regulatory effect of the vaccine on the release of the pro-inflammatory cytokines IL-1β,
TNF-α and/or IL-6 (Thacker et al. 2000; Marchioro et al. 2013). Our results were
consistent with these reports, with Suvaxyn® M. hyo vaccinates having reduced clinical
disease and significantly lower mean levels of these pro-inflammatory cytokines at 3
wpi and/or 5 wpi compared with all other treatment groups. Furthermore administration
of the Alhydrogel® and Montanide™ Gel01 formulations, which were not as successful
as the commercial bacterin in reducing mycoplasmal-induced pneumonic lesions, did
not suppress secretion of IL-1β, TNF-α and IL-6 into TBLF in response to challenge
with M. hyopneumoniae. It is unclear how immunisation with commercial bacterins
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moderates the release of these cytokines; however, levels of IL-1β, TNF-α and IL-6 in
TBLF of pigs experimentally infected with M. hyopneumoniae have previously been
shown to be positively correlated with plasminogen activation to plasmin, and that this
activation is diminished by vaccination with Suvaxyn® M. hyo (Woolley et al. 2013;
Chapter 5, Section 5.4.3). Whilst the exact role of plasmin in the chronic inflammatory
response that is the hallmark of M. hyopneumoniae infection is unclear, it has been
shown to influence the migration of inflammatory cells (Syrovets et al. 2001; Burysek
et al. 2002) and stimulate the release of pro-inflammatory cytokines (Kucharewicz et al.
2003; Li et al. 2007).
In conclusion, despite inducing strong systemic immune responses, the Alhydrogel®
and Montanide™ Gel01 formulations were unable to stimulate significant mucosal
immune responses or regulate the secretion of pro-inflammatory cytokines in response
to M. hyopneumoniae challenge; factors that were important for successful reduction of
clinical disease in Suvaxyn® M. hyo vaccinates. Notwithstanding these limitations, the
recombinant formulations offered similar protection against cilial damage of porcine
tracheal epithelium to that afforded by immunisation with the commercial bacterin. This
study highlights the need for continued research into the P97/P102 paralogs as
protective antigens and the optimisation of vaccination strategies to induce protective
immunity against M. hyopneumoniae infection.
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Chapter 5: Plasmin activity in the porcine airways is
enhanced during experimental infection with Mycoplasma
hyopneumoniae, is positively correlated with proinflammatory cytokine levels and is ameliorated by
vaccination
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5.1 Abstract
In M. hyopneumoniae infection of swine, the host immune response is considered a
major driver of lung pathology; however, the underlying inflammatory mechanisms are
not well understood. The serine protease plasmin is being increasingly recognised as a
significant player in inflammatory processes. Here we compare plasmin activity in
TBLF from pigs experimentally challenged with M. hyopneumoniae that were either
unvaccinated (n = 10), or vaccinated with the commercial vaccine Suvaxyn® M.hyo (n =
10). TBLF collected immediately prior to challenge and at 21 days and 35 days postchallenge was also assayed for levels of pro-inflammatory cytokines (TNF-α, IL-1β and
IL-6), and for bacterial load (by qPCR). Clinical signs, pathology, cytokine analyses
and qPCR all indicated that vaccinated pigs had significantly reduced disease relative to
unvaccinated animals. Plasmin activity increased significantly in TBLF collected at 21
days post-challenge compared to pre-challenge TBLF in unvaccinated (P<0.01), but not
vaccinated animals (P>0.05). A significant correlation was observed between bacterial
load and plasmin activity in the 21 days (P<0.01, r = 0.66) and the 35 days postchallenge samples, (P<0.01, r = 0.62). Plasmin activity was also significantly correlated
with levels of TNF-α, IL-1β and IL-6 at 21 days (P<0.0001, r = 0.78; P<0.0001, r =
0.77; P<0.005, r = 0.64) and with TNF-α and IL-1β at 35 days post-challenge
(P<0.0001, r = 0.77; P<0.0005, r = 0.74). Our results indicate that plasminogen is
activated to plasmin in the respiratory tract of pigs as part of the host inflammatory
response to M. hyopneumoniae infection and that this effect is ameliorated by
vaccination.
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5.2 Introduction
M. hyopneumoniae is a swine respiratory pathogen of considerable economic
significance worldwide. In the absence of identifiable M. hyopneumoniae toxins, the
host immune response to infection is considered a major driver of lung pathology;
however, the underlying inflammatory mechanisms are not well understood (Damte et
al. 2011). During infection, inflammatory exudates containing mononuclear cells
accumulate in airways and hyperplasia is observed in the BALT (Kobisch and Friis,
1996). These inflammatory changes have been associated with enhanced detection of
the pro-inflammatory cytokines IL-1β, TNF-α and IL-6 (Redondo et al. 2009; Woolley
et al. 2012; Chapter 3, Section 3.4.4). Studies on murine alveolar macrophages suggest
that M. hyopneumoniae activates NF-κB and three separate MAPK pathways (Hwang et
al. 2008; Damte et al. 2011).
Plasmin, a host-derived serine protease, is being increasingly recognised as of central
importance to the regulation of inflammatory responses. Once activated from its
zymogen precursor plasminogen, plasmin stimulates macrophage signalling via MAPK
pathways and NF-κB transcription factor, culminating in cytokine release (Syrovets et
al. 2012). Our recent studies show that a number of surface-accessible proteins within
the M. hyopneumoniae P97/P102 paralog family of adhesins interact with porcine
plasminogen (Seymour et al. 2010, 2011) and enhance its activation to plasmin
(Seymour et al. 2012). We also showed that plasminogen is readily detectable in the
fluid lining the porcine airways (Seymour et al. 2012), raising the question of whether it
plays a role in M. hyopneumoniae-mediated inflammation. In this study we examined
plasmin activity in the porcine airways before and after challenge with M.
hyopneumoniae and investigated whether vaccination had a corresponding effect on this
activity.

5.3 Materials and methods
5.3.1 Mycoplasma strain and culture
M. hyopneumoniae strain Hillcrest (Woolley et al. 2012; Chapter 3, Section 3.3.1)
was cultivated in Friis medium as previously described (Scarman et al. 1997).
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Inoculum for challenge studies contained 1-2 × 1013 CCU/mL (Freundt and Erno,
1979).

5.3.2 Vaccination, challenge and TBLF collection
Male weaner pigs (White Landrace, n = 20) were sourced from a high health status
herd at 8 weeks of age and were assigned to “vaccinated” (n = 10) and “unvaccinated”
(n = 10) groups balanced by mean weight. All pigs were housed in groups of five in a
temperature controlled (22-25°C) experimental piggery with a slatted concrete floor and
had ad libitum access to water and antibiotic-free commercial pellets (13.7 MJ A/S,
Denmark). At 9 weeks of age, pigs were anaesthetised with 10 mg/kg ketamine
(Ketamil®, Troy Laboratories, Smithfield NSW) and 1 mg/kg xylazine (Ilium Xylazil®,
Troy Laboratories) and placed in sternal recumbency. Tracheobronchial washings were
then collected by instilling 2 × 5 mL PBS into the trachea using an endotracheal tube,
followed by immediate aspiration of the fluid under vacuum. Vaccinates received 3 × 2
mL doses of Suvaxyn® M. hyo vaccine (Virbac, Australia), which were administered
intramuscularly at three weekly intervals; unvaccinated pigs did not receive any
treatment. Two weeks following the final dose of vaccine, all pigs were anaesthetised as
described above and challenged endotracheally with 10 mL M. hyopneumoniae Hillcrest
culture (Woolley et al. 2012; Chapter 3, Section 3.3.3). TBLF was collected from all
pigs as described above at 21 days and again at 35 days post-challenge. All pigs were
euthanased at 42 days post-challenge. All animal procedures were approved by the
Animal Ethics Committee at the Elizabeth Macarthur Agricultural Institute and were in
accordance with the Australian Code of Practice for the Care and Use of Animals for
Scientific Purposes.

5.3.3 Evaluation of clinical signs
Following challenge, all pigs were monitored twice daily for clinical signs of M.
hyopneumoniae infection (coughing). Cumulative (total) coughing scores were
determined as previously described (Woolley et al. 2012; Chapter 3, Section 3.3.4).
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5.3.4 Tissue sample collection and pathologic examination
At necropsy, the lungs and trachea were dissected out and lung lesions were
evaluated using the scoring system developed by Goodwin (Goodwin et al. 1969).
Samples from suspected M. hyopneumoniae lesions were collected for histopathologic
examination into neutral-buffered formalin and after fixation were embedded in
paraffin. Haematoxylin and eosin-stained sections of the lung tissue were then
examined for pathology consistent with M. hyopneumoniae infection such as
peribronchiolar and perivascular lymphoid cuffing. Lung histopathology was scored as
previously described (Woolley et al. 2012; Chapter 3, Section 3.3.7). The GLS (a
measure of the proportion of affected lung) was then multiplied by the histopathology
score (a measure of severity of inflammation) to give a measure of overall lung
pathology.

5.3.5 Determination of bacterial load in TBLF
Total DNA was extracted from 1 mL of each TBLF sample using the DNeasy Blood
and Tissue kit (Qiagen, Alameda, California). The concentration of M. hyopneumoniae
DNA in the TBLF (bacterial load) was determined using the qPCR method developed
by Strait et al. (Strait et al. 2008) and modified by Woolley et al. (2012) (Chapter 3,
Section 3.3.7).

5.3.6 Evaluation of cytokine responses in TBLF
Porcine Quantikine® ELISA kits (R&D Bio-Scientific Pty Ltd, Australia) were used,
as described previously (Woolley et al. 2012; Chapter 3, Section 3.3.6), to determine
levels of the pro-inflammatory cytokines TNF-α, IL-1β and IL-6 in TBLF.

5.3.7 Measurement of plasmin activity in TBLF
Plasmin activity in TBLF samples was measured spectrophotometrically in a
microtitre plate (Linbro Titertek, ICN Biomedicals Inc., Aurora, Ohio) using
Spectrozyme-PL (American Diagnostica Inc., Stamford, CT), a chromogenic substrate
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specifically designed for the amidolytic assay of plasmin. Test wells contained 100 µL
aliquots of TBLF. Positive control wells contained 1 µg purified porcine plasminogen
(Seymour et al. 2012) that had been pre-incubated with 200 U tissue plasminogen
activator (tPA) for 1 hr at 37°C to activate the plasminogen to plasmin. Negative control
wells contained plasminogen but no tPA. To determine plasmin activity, 20 µL per well
of 2.5 mM Spectrozyme-PL was added to all samples and controls. Immediately
following the addition of the Spectrozyme-PL, an initial plate reading was performed
(A405nm), and then the plate was incubated at 37°C with shaking. Further absorbance
readings were taken over a 20 hr period. All samples were tested in duplicate.

5.3.8 Statistical analyses
All statistical analyses were conducted using GraphPad Prism 4 (GraphPad, San
Diego, California). Paired t tests were used to determine whether mean pathology and
coughing scores were statistically different between the vaccinated and unvaccinated
groups. ANOVA was used to compare the effect of vaccination on bacterial load, proinflammatory cytokine levels and plasmin activity in the TBLF. Prior to determining
correlations, data were transformed by taking the square root of each parameter.
Pearson’s correlation test was then used to determine whether there was a linear
relationship between data sets and a P-value for each correlation was also determined.
Results with a P-value of < 0.05 were considered to be statistically significant.

5.4 Results
5.4.1 Clinical disease and bacterial load in TBLF
To determine whether vaccination ameliorated clinical disease and reduced M.
hyopneumoniae load in the upper respiratory tract, all pigs were assessed for coughing
severity, macroscopic and microscopic lesions (pathology scores) and bacterial load in
TBLF. No coughing was observed in pigs from either group prior to challenge and as
expected TBLF collected from all pre-challenged pigs were negative for M.
hyopneumoniae based on the cut-off value (<0.023ng/µL) determined in a previous
study (Woolley et al. 2012; Chapter 3, Section 3.4.5). Following challenge, mean
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coughing scores were significantly higher in unvaccinated pigs (0.189 ± 0.025)
compared to vaccinated pigs (0.043 ± 0.013) (P<0.0001). Similarly, the pathology
scores for unvaccinated pigs (5.388 ± 2.066) were significantly greater than those
determined for vaccinated pigs (0.675 ± 0.346) (P<0.05). This reflects the significantly
elevated bacterial load detected in TBLF from pigs in the unvaccinated group at 21 days
and 35 days post-challenge (mean DNA concentration 75-80 ng/µL) compared with
those in the vaccinated pigs (2-10 ng/µL) at the same timepoints.

5.4.2 Analysis of pro-inflammatory cytokines in TBLF
Increased levels of the pro-inflammatory cytokines TNF-α (Lorenzo et al. 2006;
Redondo et al. 2009), IL-1β (Lorenzo et al. 2006; Redondo et al. 2009; Woolley et al.
2012; Chapter 3, Section 3.4.4) and IL-6 (Choi et al. 2006; Woolley et al. 2012; Chapter
3, Section 3.4.4) in the TBLF of M. hyopneumoniae-infected pigs have been reported in
prior studies. We aimed to determine whether there was a measurable difference in
levels of these cytokines between vaccinated and unvaccinated pigs after M.
hyopneumoniae challenge. Prior to challenge, the mean levels of TNF-α, IL-1β and IL-6
in TBLF from both vaccinated and unvaccinated pigs were found to be low and within a
clinically normal range. As expected, mean levels of all pro-inflammatory cytokines
increased at 21 days post-challenge and subsided by 35 days post-challenge (Figure
5.1). The increase in mean levels of TNF-α, IL-1β and IL-6 at 21 days post-challenge
compared to the pre-challenge samples was statistically significant (P<0.001, P<0.001
and P<0.05 respectively) in unvaccinated but not in vaccinated pigs. Furthermore,
analysis of variance indicated that mean TNF-α, IL-1β and IL-6 levels were statistically
higher in unvaccinated pigs compared to vaccinated pigs (P<0.05, P<0.001 and P<0.05
respectively) at 21 days post-challenge. Mean cytokine levels between the two groups at
35 days post-challenge were not statistically different (Figure 5.1).
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Figure 5.1 Comparison of mean levels of the pro-inflammatory cytokines TNF-α (A), IL-1β (B)
and IL-6 (C) in the TBLF of pigs prior to challenge with M. hyopneumoniae (D0) and at 21 days
(D21) and 35 days (D35) post-challenge. Unvaccinated pigs (U, light grey bars) displayed
significantly higher levels of each cytokine at 21 days post-challenge in comparison to the
vaccinated (V, dark grey bars) at the same timepoint. Cytokine levels had subsided by 35 days
post-challenge. Error bars indicate the standard error of the mean. *P<0.05, **P<0.001.

5.4.3 Plasmin activity in TBLF
Given that pigs in the unvaccinated group displayed significantly higher levels of M.
hyopneumoniae, inflammatory factors and clinical signs of disease compared to
vaccinated pigs, we aimed to determine whether plasmin activity was also elevated in
unvaccinated compared to vaccinated animals. Plasmin activity was measured in TBLF
collected from pigs prior to vaccination and again at 21 days and 35 days postchallenge. In the unvaccinated pigs, a statistically significant increase in plasmin
activity (P<0.01) was observed at 21 days post-challenge, representing a 2-fold increase
in activity relative to the pre-challenge samples. Mean plasmin activity remained
slightly elevated (1.6-fold higher than pre-challenge) in the unvaccinated pigs at 35 days
post-challenge; however, this difference was not found to be statistically significant.
The vaccinates displayed only a modest increase in plasmin activity post-challenge (1.11.4-fold increase), which was not a statistically significant increase at 21 days or at 35
days post-challenge (P>0.05) (Figure 5.2).
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Figure 5.2 Comparison of mean plasmin activity in the TBLF of pigs prior to challenge (D0)
with M. hyopneumoniae and at 21 (D21) days and 35 (D35) days post-challenge. There was no
significant change in plasmin activity in the vaccinated pigs (V, dark grey bars) post-challenge;
however, there was a significant (2-fold) increase in plasmin activity in the TBLF from
unvaccinated pigs (U, light grey bars) at 21 days post-challenge compared to the pre-challenge
TBLF. The difference in plasmin activity between vaccinated and unvaccinated pigs was also
significant at 21 days post-challenge. Error bars indicate the standard error of the mean.
*P<0.05, **P<0.001.

5.4.4 Relationship between plasmin activity and bacterial load
M. hyopneumoniae is known to contain a number of plasminogen-binding proteins, at
least one of which can enhance the tPA-induced activation of plasminogen to plasmin in
vitro. Therefore, we examined whether bacterial load and plasmin activity in the TBLF
from individual pigs were correlated when examined across both treatment groups. We
found a moderate positive and significant relationship between these two parameters at
both 21 days (r = 0.66, P<0.05) and 35 days post-challenge (r = 0.62, P<0.05) (Figure
5.3, A-B), and also when all timepoints were examined together (r = 0.58, P<0.05)
(Figure 5.3, C).
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Figure 5.3 Correlation between bacterial load (M. hyopneumoniae (Mhp) DNA concentration)
and plasmin activity in the TBLF of pigs at 21 days post-challenge (A), 35 days post-challenge
(B) and at all timepoints combined (C). Unvaccinated pigs (white squares), vaccinated pigs
(black squares), pre-challenged pigs (grey squares). Correlation coefficients and P-values are
indicated.

5.4.5 Relationship between plasmin activity and pro-inflammatory cytokine levels
Given that the plasminogen activation system has been implicated in a number of
inflammatory processes, we examined whether a relationship existed between plasmin
activity and the levels of the pro-inflammatory cytokines TNF-α, IL-1β and IL-6 in
TBLF from all pigs challenged with M. hyopneumoniae. Levels of TNF-α and IL-1β
were strongly (and positively) correlated with plasmin activity at 21 days post-challenge
(r = 0.78, P<0.0001; r = 0.77, P<0.0001; Figure 5.4, A-B) and at 35 days post-challenge
(r = 0.77, P<0.005; r = 0.74, P<0.0001; Figure 5.4, C-D) with M. hyopneumoniae. IL-6
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levels were moderately correlated with plasmin activity at 21 days post-challenge (r =
0.64, P<0.0005; Figure 5.4, E), but at 35 days post-challenge no correlation was evident
as IL-6 was no longer detectable in any of the pigs while plasmin levels remained
somewhat elevated.
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Figure 5.4 Correlation between levels of TNF-α (A, D), IL-1β (B, E) and IL-6 (C) and plasmin
activity at 21 days and 35 days post-challenge. Unvaccinated pigs (white squares), vaccinated
pigs (black squares). Correlation coefficients and P-values are indicated.

5.5 Discussion and conclusions
The purpose of this study was to examine plasmin activity in the porcine airway
during M. hyopneumoniae infection and to determine whether vaccination had a
significant effect on this activity. We also examined the relationship between plasmin
activity and levels of pro-inflammatory cytokines in the porcine respiratory tract in
vaccinated and unvaccinated pigs. Clinical data (coughing) and pathology scores
indicated that vaccinated pigs had significantly reduced disease relative to the
unvaccinated pigs. A reduction in the levels of known mediators of inflammation
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associated with M. hyopneumoniae infection, the pro-inflammatory cytokines TNF-α
and IL-1β and IL-6 (Choi et al. 2006; Lorenzo et al. 2006; Redondo et al. 2009;
Woolley et al. 2012; Chapter 3, Section 3.4.4), in the vaccinates also supported the
clinical data in demonstrating that inflammation was significantly ameliorated in these
animals. Bacterin formulations have been shown in prior studies to reduce clinical signs
of disease, although they do not prevent colonisation by M. hyopneumoniae (Strait et al.
2007; Thacker et al. 1998; Thacker et al. 2000). In this study, we confirmed that
vaccination did not completely block M. hyopneumoniae colonisation; however, we
were able to use qPCR to demonstrate that the bacterial load in the vaccinates was
significantly reduced. In the unvaccinated pigs, all measures of disease were higher at
21 days than at 35 days post-challenge, suggesting that pigs were in a recovery phase by
the sixth week after challenge. This is consistent with prior studies where microscopic
lesions and other measures of inflammation began to decrease at 21-28 days postchallenge (Redondo et al. 2009).
Based on these combined data we were able to make a comparison of plasmin activity
in the airways of uninfected (pre-challenge) pigs, partially protected (vaccinated) pigs
and unprotected pigs. The unvaccinated pigs displayed a significant increase in plasmin
activity at 21 days post-challenge (2-fold increase), a time point at which other
measures of disease were also elevated. This finding, combined with the fact that there
was no statistically significant increase in plasmin activity in the vaccinated pigs,
suggests that plasmin plays an important role in M. hyopneumoniae pathogenesis. It is
likely that plasmin activity detected in the TBLF is an underestimate of total plasmin
activity in the lung because sampling was restricted to the airways and does not account
for cell-associated plasmin activity (Nishiuma et al. 2004). Despite this, prior studies
indicate that 1.5 to 3-fold increases in plasmin activity have significant physiological
effects on processes as diverse as fibrin clot breakdown (Sawa et al. 1996; Hu et al.
2012), extracellular matrix degradation (Mollmark et al. 2012) tumour cell invasion
(Choi et al. 2003), inflammatory cell migration (Gong et al. 2008; Wygrecka et al.
2009) and reproductive processes (Dow et al. 2002). Therefore the 2-fold increase in
plasmin activity detected in the TBLF in this study is physiologically relevant.
Given that a marked subacute to chronic cellular inflammatory response in the
respiratory tract is a hallmark of M. hyopneumoniae infection (Kobisch and Friis, 1996;
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Sarradell et al. 2003; Redondo et al. 2009) while fibrin deposition is not, we suspect that
the role of plasmin in the airways is most likely related to inflammation. Indeed, the
plasminogen activation system is being increasingly recognised as a central pathway in
the inflammatory process with plasmin affecting the activity and behaviour of
inflammatory cells (Syrovets et al. 2001, 2012; Burysek et al. 2002). Specifically,
plasmin has been shown to directly or indirectly influence the migration of monocytes,
macrophages and lymphocytes (Falcone et al. 2001; Burysek et al. 2002; Swaisgood et
al. 2007) and to stimulate the release of the pro-inflammatory cytokines IL-1, TNF- α
and IL-6 at the site of inflammatory reaction (Kucharewicz et al. 2003; Li et al. 2007;
Syrovets et al. 2012). Plasmin has also been implicated in the chronic lung
inflammation and airway remodelling observed in asthma patients and has been
identified as an important therapeutic target (Kucharewicz et al. 2003; Swaisgood et al.
2007). Indeed, it has been demonstrated that plasminogen-deficient mice have decreased
perivascular and peribronchiolar leukocytosis, cytokine and mucus production in
response to ovalbumin-induced pulmonary challenge (Swaisgood et al. 2007).
Interestingly, we found that plasmin activity in the TBLF of M. hyopneumoniaeinfected pigs is strongly correlated with levels of TNF-α and IL-1β at 21 days and 35
days post-challenge. The relationship with IL-6 is less clear, although plasmin activity
is significantly correlated with IL-6 levels at 21 days post-challenge. Together, these
data point to a role for plasmin in M. hyopneumoniae-induced inflammation. Although
the exact role of plasmin in this process remains unclear, this protease has been shown
to stimulate intracellular MAPK signalling cascades via proteolytic cleavage of the
macrophage surface molecule annexin A2 (Li et al. 2007). Interestingly, M.
hyopneumoniae is known to stimulate three separate MAPK pathways in murine
alveolar macrophages (Damte et al. 2011) although the mechanism by which these
cascades are triggered has not been identified. Given that plasminogen is readily
available in the porcine airways (Seymour et al. 2012) and that plasmin activity is
enhanced during M. hyopneumoniae infection, plasmin can be considered a potential
mediator of this process.
In this study, we were able to demonstrate a positive relationship between bacterial
load and plasmin activity in the porcine airways. However, it is currently unclear
whether an enhanced inflammatory response to the higher bacterial load in unvaccinated
pigs is the sole driver of increased plasmin activity, or whether M. hyopneumoniae cells
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are directly involved in this activity. Unlike certain species of Staphylococcus and
Streptococcus that contain bacterial activators of plasminogen (staphylokinase and
streptokinase) (Collen and Lijnen, 1994; Bisno et al. 2003), M. hyopneumoniae is
unable to directly activate plasminogen to plasmin. Nonetheless, we previously
identified a number of plasminogen-binding proteins within M. hyopneumoniae,
including the surface-associated molecule P102, which can enhance the tPA-mediated
activation of bound plasminogen (Seymour et al. 2012). On inflammatory cells,
plasminogen can be activated to plasmin at the cell surface and the effects of plasmin
are thereby exerted locally. Similarly, it is possible that M. hyopneumoniae cells
colonising the porcine airways enhance the activation of plasminogen at the bacterial
cell surface enabling the bacterium to influence its immediate environment. Such effects
could include proteolytic degradation of the extracellular matrix, which may help to
explain how M. hyopneumoniae mediates epithelial cell damage. Given that
plasminogen is viewed a potential therapeutic target in sufferers of chronic
inflammatory lung disease such as asthma (Swaisgood et al. 2007), it is possible that it
may also be a useful target in reducing disease severity during M. hyopneumoniae
infection.
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Chapter 6: General discussion and future studies

M. hyopneumoniae is a contagious respiratory pathogen of swine which causes
significant economic losses to the pig production industry. Lung pathology is largely
attributed to the host immune response to infection; however, the underlying
inflammatory mechanisms are ill-defined (Damte et al. 2011). Commercial bacterinbased vaccines can reduce the clinical signs of disease (Ross et al. 1986); however, they
do not prevent the transmission or establishment of M. hyopneumoniae in lungs, thus
rationalising the development of alternative vaccines (Thacker et al. 2000). The aim of
this thesis was to evaluate the protective efficacy of recombinant subunit vaccines
against mycoplasmal pneumonia, relative to the commercial bacterin Suvaxyn® M. hyo.
Experimental infection models are essential for evaluating vaccine efficacy, and are
dependent upon challenge strains known to induce clinical signs of disease (Vicca et al.
2003; Meyns et al. 2007). To identify a suitable challenge strain for use in our
recombinant vaccine trial, two M. hyopneumoniae field isolates (Hillcrest and Beaufort)
were compared for their abilities to induce mycoplasmal pneumonia in pigs following
experimental infection. The Hillcrest strain was found to be superior to Beaufort in its
ability to induce clinical signs, lung pathology and pro-inflammatory cytokine responses
that were indicative of mild-to-moderate mycoplasmal pneumonia, and thereafter
employed as the challenge strain.
The biological rationale for the differences in Hillcrest and Beaufort strain virulence
was not determined in this study; however, a recent comparative genomic analysis of
the pathogenic M. hyopneumoniae strain 168 and its laboratory-attenuated equivalent
(strain 168-L) identified mutations in coding sequences for mycoplasma adhesins (P97,
P102, P146, P159, P216 and LppT), surface antigens (P36 and P65), a cell envelope
protein (P95), a secretory and chaperone protein (DnaK), and components of energy and
intermediary metabolism (Lui et al. 2013). Although the relative significance of
mutations in these genes in the attenuation of virulence is unknown (Lui et al. 2013), it
may offer a partial explanation for the differences in M. hyopneumoniae strain
pathogenicity observed in our study.
Several of the putative virulence determinants identified by Lui et al. (2013) as
varying between pathogenic and non-pathogenic strains belong to the p97/p102 paralog
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families. The P97/P102 paralogs are endoproteolytically cleaved to generate an
assortment of cell-associated cleavage fragments which are alleged to not only allow M.
hyopneumoniae to vary its surface architecture and evade host immune responses, but
also to facilitate pathogenesis by exploiting host surface glycoconjugates and
extracellular matrix components (Zhang et al. 1995; Djordjevic et al. 2004; Burnett et
al. 2006; Jenkins et al. 2006; Wilton et al. 2009; Deutscher et al. 2010, 2012; Bogema et
al. 2011, 2012; Seymour et al. 2010, 2011, 2012). The P97/P102 paralogs therefore
represent promising vaccine candidates. Here we evaluated recombinant fragments
representing functional domains of several of the P97/P102 paralogs formulated with
Alhydrogel® and Montanide™ Gel01 as vaccines against mycoplasmal pneumonia in
pigs experimentally infected with the Hillcrest strain. Although the Alhydrogel®- and
Montanide™ Gel01-adjuvanted antigens were immunoreactive against serum from
challenged swine, the recombinant vaccines did not offer any superior protection against
M. hyopneumoniae infection, relative to that afforded by administration of Suvaxyn® M.
hyo. Superiority of the commercial bacterin was associated with elevated levels of
mucosal antibodies and lower levels of pro-inflammatory cytokines in the respiratory
tract of challenged pigs, relative to those detected in the recombinant vaccinates and
unvaccinated swine. There was also a strong and positive correlation between proinflammatory cytokine responses and plasmin activity in the porcine respiratory tract of
Hillcrest-challenged pigs. Moreover, plasmin activity was significantly diminished by
administration of Suvaxyn® M. hyo. Collectively these results support the likelihood of
secretory IgA having a functional role in immunity against M. hyopneumoniae (Thacker
et al. 1998, 2000; Marchioro et al. 2013). Likewise, our results validate the relationship
described between elevated pro-inflammatory cytokine responses and the occurrence of
pneumonic lesions in M. hyopneumoniae-infected pigs (Choi et al. 2006; Thacker et al.
2006), and suggest that plasminogen activation is a mediator of this process.
In conclusion, further examination of gene expression profiles for pathogenic and
non-pathogenic M. hyopneumoniae isolates and the mechanisms contributing to strain
virulence is necessary, and may help to identify efficacious vaccine candidates (Lui et
al. 2013). Whilst our recombinant vaccines did not evoke immunity against M.
hyopneumoniae, the potential worth of the P97/P102 paralogs as protective antigens
ought not to be disregarded. Rather, avenues for inducing mucosal immune responses
and reducing host-mediated immunopathological changes in pigs exposed to M.
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hyopneumoniae should be a focus of future vaccination strategies. Perhaps priming for
effective immune responses may be achieved through the use of adjuvants and/or
delivery systems, such as replication-defective adenovirus vectors or nanoparticles,
which present the vaccine candidate to the respiratory mucosa (Torres et al. 1995;
Rosenthal et al. 1996; Papp et al. 1998; Mahapatro and Singh, 2011; Simionatto et al.
2013). Humoral immunity may possibly be induced by regimes which combine
subcutaneous priming with booster immunisation via the mucosal route (Crouch et al.
2005; Ralli-Jain et al. 2010; Hausner et al. 2013), and also warrant future investigation.
As for other chronic inflammatory lung diseases (Swaisgood et al. 2007), plasminogen
may be a potential therapeutic target for reducing the severity of mycoplasmal
pneumonia, and thus the mechanisms by which Suvaxyn® M. hyo abolishes plasmin
activity should be a focus of future research. Finally, pro-inflammatory cytokines play
an essential role in lung histopathology associated with mycoplasmal pneumonia, and
are also known to negatively impact on animal metabolism and feed intake (Elsasser et
al. 1995; Finck and Johnson, 2000; Broussard et al. 2001). To this end, further research
into plasminogen activation as a mediator for host inflammatory responses and how this
process may affect productivity is required to potentially diminish the effects of M.
hyopneumoniae infection on pig husbandry, from both an economical and ethical
standpoint.
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Appendix
Growth and Nutrient Media
Hanks buffered salt solution for modified Friis medium
Hanks A
Sodium chloride

80 g/500 mL

Potassium chloride

4 g/500 mL

Magnesium sulphate heptahydrate

1 g/500 mL

Magnesium chloride

1 g/500 mL

Calcium chloride

1.4 g/500 mL

Hanks B
Sodium hydrogen orthophosphate

1.5 g/500 mL

Potassium dihydrogen orthophosphate

0.6 g/500 mL

0.5% phenol red (pH to 7.0)
Phenol red

0.5 g/100 mL

1 M sodium hydroxide

1.1 mL/100 mL

Yeast extract
Saccharomyces cerevisiae (Baker’s yeast) type II

167 g/L

Modified Friis medium (pH 7.4)
Hanks A

15.2 mL

Hanks B

15.2 mL

Brain heart infusion

4.9 g

PPLO without CV

5.25 g

0.5% phenol red

2.6 mL

Milli-Q water

827 mL

Bacitracin

0.144 g/5.7 mL
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Amplicillin

0.144 g/5.7 mL

Yeast extract

34 mL

Horse serum

50 mL

Pig serum

50 mL

LB broth
Tryptone

10 g/L

Yeast extract

5 g/L

Sodium chloride

5 g/L

LB agar
Tryptone

10 g/L

Yeast extract

5 g/L

Sodium chloride

5 g/L

Agar

15 g/L

Buffer Solutions

PBS (pH 7.2)
Sodium chloride

8 g/L

Potassium chloride

0.2 g/L

Sodium hydrogen phosphate

1.15 g/L

Potassium dihydrogen phosphate

0.30 g/L

5× TBE buffer (stock solution)
Tris(hydroxymethyl)aminomethane

54 g/L

Boric acid

27.5 g/L

0.5 M EDTA (pH 8.0)

20 mL/L
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0.5× TBE running buffer (working solution)
5× TBE buffer

100 mL/L

Milli-Q water

900 mL/L

Agarose gel electrophoresis reagents

Loading dye
Bromophenol blue

0.25% (w/v)

Ficoll

15% (w/v)

Recombinant 6×His-tagged protein purification buffers

Buffer B (pH 8.0)
Urea

8M

Sodium dihydrogen orthophosphate

0.1 M

Tris

0.01 M

Buffer C (pH 6.3)
Urea

8M

Sodium dihydrogen orthophosphate

0.1 M

Tris

0.01 M

Buffer D (pH 5.9)
Urea

8M

Sodium dihydrogen orthophosphate

0.1 M

Tris

0.01 M
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Buffer E (pH 4.5)
Urea

8M

Sodium dihydrogen orthophosphate

0.1 M

Tris

0.01 M

Recombinant GST-tagged protein purification buffers

Native lysis buffer
Lysozyme

10 mg/mL

Tris-HCl (pH 8.0)

25 mM

Glutathione elution buffer (pH 8.0)
Tris-HCl

50 mM

Reduced glutathione

10 mM

SDS-PAGE reagents

12% polyacrylamide resolving gel (4 gels)
Milli-Q water

13.2 mL

30% acrylamide-bis solution (29:1)

16.0 mL

1.5 M Tris (pH 8.8)

10.0 mL

10% (w/v) SDS

400 µL

Ammonium persulphate

45 mg

TEMED

16 µL
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4% polyacrylamide stacking gel (4 gels)
Milli-Q water

10.83 mL

30% acrylamide-bis solution (29:1)

1.95 mL

1 M Tris (pH 6.8)

1.95 mL

10% (w/v) SDS

400 µL

Ammonium persulphate

45 mg

TEMED

16 µL

Cracking buffer (4×)
1 M Tris (pH 6.8)

60 mM

SDS

1 g/100 mL

Β-mercaptoethanol

1 g/100 mL

Glycerol

10 g/ 100 mL

Bromophenol blue

0.1 g/100 mL

10× SDS-PAGE buffer (stock solution)
Tris

250 mM

Glycine

1.92 M

SDS

1% (w/v)

1× SDS-PAGE buffer (working solution)
10× SDS-PAGE buffer

100 mL/L

Milli-Q water

900 mL/L
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